WO2008024746A1 - 4-substituted phenoxyphenylacetic acid derivatives - Google Patents
4-substituted phenoxyphenylacetic acid derivatives Download PDFInfo
- Publication number
- WO2008024746A1 WO2008024746A1 PCT/US2007/076378 US2007076378W WO2008024746A1 WO 2008024746 A1 WO2008024746 A1 WO 2008024746A1 US 2007076378 W US2007076378 W US 2007076378W WO 2008024746 A1 WO2008024746 A1 WO 2008024746A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- group
- methyl
- phenyl
- Prior art date
Links
- -1 4-substituted phenoxyphenylacetic acid Chemical class 0.000 title claims description 97
- 150000001875 compounds Chemical class 0.000 claims abstract description 128
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 208000026278 immune system disease Diseases 0.000 claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 83
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 79
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 33
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 26
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010028735 Nasal congestion Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000005547 chronic conjunctivitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 101150034985 Ptgdr2 gene Proteins 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 180
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 149
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
- 238000006243 chemical reaction Methods 0.000 description 112
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 235000019439 ethyl acetate Nutrition 0.000 description 64
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 55
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000010410 layer Substances 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 238000003756 stirring Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 23
- 239000012267 brine Substances 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 229910000029 sodium carbonate Inorganic materials 0.000 description 18
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 239000002585 base Substances 0.000 description 14
- 239000013058 crude material Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 11
- ACIMQXSSGMWVKG-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)ethanamine Chemical compound NCCC1=C(Cl)C=CC=C1Cl ACIMQXSSGMWVKG-UHFFFAOYSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 235000011181 potassium carbonates Nutrition 0.000 description 9
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical group ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical group NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 8
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 6
- 0 *C(*)(C(*)=O)c(cc1CN)cc(*)c1Oc(cc1)cc(*)c1I Chemical compound *C(*)(C(*)=O)c(cc1CN)cc(*)c1Oc(cc1)cc(*)c1I 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 4
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 4
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 4
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 4
- 150000008046 alkali metal hydrides Chemical class 0.000 description 4
- 125000006242 amine protecting group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- XGDZEDRBLVIUMX-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1 XGDZEDRBLVIUMX-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 3
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- IWXJBVIYCDMWHX-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-4-hydroxybenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 IWXJBVIYCDMWHX-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- KQFYNURGIZFXQL-UHFFFAOYSA-N tert-butyl 2-(3-cyano-4-fluorophenyl)acetate Chemical compound CC(C)(C)OC(=O)CC1=CC=C(F)C(C#N)=C1 KQFYNURGIZFXQL-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 description 2
- QPVWRFSVMBTLNG-UHFFFAOYSA-N 2-[3-cyano-4-[4-[(2-phenylcyclopropyl)carbamoyl]phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NC2C(C2)C=2C=CC=CC=2)C=C1 QPVWRFSVMBTLNG-UHFFFAOYSA-N 0.000 description 2
- UMPPTBPWPCPZFQ-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(3-methoxyphenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound COC1=CC=CC(CCNC(=O)C=2C=CC(OC=3C(=CC(CC(O)=O)=CC=3)C#N)=CC=2)=C1 UMPPTBPWPCPZFQ-UHFFFAOYSA-N 0.000 description 2
- VNTMJVRXRDIATN-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(4-methylphenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound C1=CC(C)=CC=C1CCNC(=O)C(C=C1)=CC=C1OC1=CC=C(CC(O)=O)C=C1C#N VNTMJVRXRDIATN-UHFFFAOYSA-N 0.000 description 2
- SUVXKBPDKSACKX-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 SUVXKBPDKSACKX-UHFFFAOYSA-N 0.000 description 2
- AZHLDAIQQLBAOO-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-phenylphenyl]acetic acid Chemical compound C=1C=CC=CC=1C1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 AZHLDAIQQLBAOO-UHFFFAOYSA-N 0.000 description 2
- GNRRBHUAJFYMJW-UHFFFAOYSA-N 2-[4-[4-[[1-(4-chlorophenyl)cyclopropyl]methylcarbamoyl]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCC2(CC2)C=2C=CC(Cl)=CC=2)C=C1 GNRRBHUAJFYMJW-UHFFFAOYSA-N 0.000 description 2
- ZQQHAKWFOCNXKF-UHFFFAOYSA-N 3,4-dichloro-n-(4-hydroxyphenyl)benzamide Chemical compound C1=CC(O)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 ZQQHAKWFOCNXKF-UHFFFAOYSA-N 0.000 description 2
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 101000666385 Homo sapiens Transcription factor Dp-2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229910013596 LiOH—H2O Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 101710201263 Prostaglandin D2 receptor 2 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FBMWURVKVTYTGV-UHFFFAOYSA-N ethyl 2-[3-bromo-4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]phenyl]acetate Chemical compound BrC1=CC(CC(=O)OCC)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 FBMWURVKVTYTGV-UHFFFAOYSA-N 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 102000055674 human TFDP2 Human genes 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- AXONPFSLAZILIE-UHFFFAOYSA-N methyl 2-(3-fluoro-4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C(F)=C1 AXONPFSLAZILIE-UHFFFAOYSA-N 0.000 description 2
- AYIBMTKOTXNBQP-UHFFFAOYSA-N methyl 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-methoxyphenyl]acetate Chemical compound COC1=CC(CC(=O)OC)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 AYIBMTKOTXNBQP-UHFFFAOYSA-N 0.000 description 2
- RXFDIHKNMYKAHO-UHFFFAOYSA-N methyl 4-[2-cyano-4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]phenoxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OC1=CC=C(CC(=O)OC(C)(C)C)C=C1C#N RXFDIHKNMYKAHO-UHFFFAOYSA-N 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- OTKFCIVOVKCFHR-UHFFFAOYSA-N (Methylsulfinyl)(methylthio)methane Chemical compound CSCS(C)=O OTKFCIVOVKCFHR-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- KXUGUWTUFUWYRS-UHFFFAOYSA-N 1-methylimidazole-4-sulfonyl chloride Chemical compound CN1C=NC(S(Cl)(=O)=O)=C1 KXUGUWTUFUWYRS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VHJKDOLGYMULOP-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1Cl VHJKDOLGYMULOP-UHFFFAOYSA-N 0.000 description 1
- DOBONCGSXZWPIJ-UHFFFAOYSA-N 2-(3-cyano-4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(C#N)=C1 DOBONCGSXZWPIJ-UHFFFAOYSA-N 0.000 description 1
- YRFBZAHYMOSSGX-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(O)C(F)=C1 YRFBZAHYMOSSGX-UHFFFAOYSA-N 0.000 description 1
- VQLXPSANRSPTEZ-UHFFFAOYSA-N 2-(4-chlorophenyl)cyclopropan-1-amine Chemical compound NC1CC1C1=CC=C(Cl)C=C1 VQLXPSANRSPTEZ-UHFFFAOYSA-N 0.000 description 1
- XAEAUZAGDOXYIE-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonylamino]acetic acid Chemical compound OC(=O)CNS(=O)(=O)C1=CC=C(F)C=C1 XAEAUZAGDOXYIE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XVQDYPCNGOHWRO-UHFFFAOYSA-N 2-[3-(acetamidomethyl)-4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]phenyl]acetic acid Chemical compound CC(=O)NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 XVQDYPCNGOHWRO-UHFFFAOYSA-N 0.000 description 1
- FRJYUTCPJMAZSA-UHFFFAOYSA-N 2-[3-(methanesulfonamidomethyl)-4-[4-(phenylcarbamoyl)phenoxy]phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1 FRJYUTCPJMAZSA-UHFFFAOYSA-N 0.000 description 1
- OZKQHSUPRRZQNJ-UHFFFAOYSA-N 2-[3-(methanesulfonamidomethyl)-4-[4-[2-[3-(trifluoromethyl)phenyl]ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=C(C=CC=2)C(F)(F)F)C=C1 OZKQHSUPRRZQNJ-UHFFFAOYSA-N 0.000 description 1
- ZTOUDBPQHWAQKU-UHFFFAOYSA-N 2-[3-(methanesulfonamidomethyl)-4-[4-[[4-(trifluoromethyl)phenyl]carbamoyl]phenoxy]phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)C=C1 ZTOUDBPQHWAQKU-UHFFFAOYSA-N 0.000 description 1
- BTLGYCIABRKJDN-UHFFFAOYSA-N 2-[3-[(1,3-dioxoisoindol-2-yl)methyl]-4-hydroxyphenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(O)C(CN2C(C3=CC=CC=C3C2=O)=O)=C1 BTLGYCIABRKJDN-UHFFFAOYSA-N 0.000 description 1
- ZCEDRLJHNKDRBJ-UHFFFAOYSA-N 2-[3-[(cyclohexanecarbonylamino)methyl]-4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]phenyl]acetic acid Chemical compound C1CCCCC1C(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 ZCEDRLJHNKDRBJ-UHFFFAOYSA-N 0.000 description 1
- WZDDSKHKSNYVSZ-UHFFFAOYSA-N 2-[3-cyano-4-[4-(1,2,3,4-tetrahydronaphthalen-2-ylcarbamoyl)phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NC2CC3=CC=CC=C3CC2)C=C1 WZDDSKHKSNYVSZ-UHFFFAOYSA-N 0.000 description 1
- BBHSEVSJFHURJU-UHFFFAOYSA-N 2-[3-cyano-4-[4-(2-phenylethylcarbamoyl)phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC=CC=2)C=C1 BBHSEVSJFHURJU-UHFFFAOYSA-N 0.000 description 1
- GQWUXWGRBCQNGK-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(2,4-dichlorophenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 GQWUXWGRBCQNGK-UHFFFAOYSA-N 0.000 description 1
- VBUAISCHCBVIEQ-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(2,6-dichlorophenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C(=CC=CC=2Cl)Cl)C=C1 VBUAISCHCBVIEQ-UHFFFAOYSA-N 0.000 description 1
- HLCMSNAONPTSTC-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(3-fluorophenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=C(F)C=CC=2)C=C1 HLCMSNAONPTSTC-UHFFFAOYSA-N 0.000 description 1
- RCXKIHBEWQEVNI-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(4-fluorophenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(F)=CC=2)C=C1 RCXKIHBEWQEVNI-UHFFFAOYSA-N 0.000 description 1
- OQIFQHIGUKXNQT-UHFFFAOYSA-N 2-[3-cyano-4-[4-[2-(4-methoxyphenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCNC(=O)C(C=C1)=CC=C1OC1=CC=C(CC(O)=O)C=C1C#N OQIFQHIGUKXNQT-UHFFFAOYSA-N 0.000 description 1
- PJPFNAJCEXEVPS-UHFFFAOYSA-N 2-[4-[4-(2-anilino-2-oxoethyl)phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1CC(=O)NC1=CC=CC=C1 PJPFNAJCEXEVPS-UHFFFAOYSA-N 0.000 description 1
- HZWZALRGUIUJMY-UHFFFAOYSA-N 2-[4-[4-(benzylcarbamoyl)phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1 HZWZALRGUIUJMY-UHFFFAOYSA-N 0.000 description 1
- WVFFCOFGRIUMDE-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-(methanesulfonamidomethyl)phenyl]-2-methylpropanoic acid Chemical compound CS(=O)(=O)NCC1=CC(C(C)(C(O)=O)C)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 WVFFCOFGRIUMDE-UHFFFAOYSA-N 0.000 description 1
- FAQRSMNNJBHVRN-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-[(methoxycarbonylamino)methyl]phenyl]acetic acid Chemical compound COC(=O)NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 FAQRSMNNJBHVRN-UHFFFAOYSA-N 0.000 description 1
- AZABPOZXQMDWKR-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-[(pyridin-3-ylsulfonylamino)methyl]phenyl]acetic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 AZABPOZXQMDWKR-UHFFFAOYSA-N 0.000 description 1
- FWKRDGRNQGJQPD-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-[(pyridine-3-carbonylamino)methyl]phenyl]acetic acid Chemical compound C=1C=CN=CC=1C(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 FWKRDGRNQGJQPD-UHFFFAOYSA-N 0.000 description 1
- QXADRHMZWVAIAX-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-[(pyridine-4-carbonylamino)methyl]phenyl]acetic acid Chemical compound C=1C=NC=CC=1C(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 QXADRHMZWVAIAX-UHFFFAOYSA-N 0.000 description 1
- PJSOQGUCKVZZQP-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-[[(2,4-dichlorophenyl)sulfonylamino]methyl]phenyl]acetic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1S(=O)(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 PJSOQGUCKVZZQP-UHFFFAOYSA-N 0.000 description 1
- QAALQOVJHJFBLM-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-methoxyphenyl]acetic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 QAALQOVJHJFBLM-UHFFFAOYSA-N 0.000 description 1
- QTDXYHSAWJVOEN-UHFFFAOYSA-N 2-[4-[4-[(3,4-dichlorophenyl)carbamoyl]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NC=2C=C(Cl)C(Cl)=CC=2)C=C1 QTDXYHSAWJVOEN-UHFFFAOYSA-N 0.000 description 1
- YIWGQUJEAHOECZ-UHFFFAOYSA-N 2-[4-[4-[(3,4-difluorobenzoyl)amino]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(F)C(F)=C1 YIWGQUJEAHOECZ-UHFFFAOYSA-N 0.000 description 1
- KUKXAEMVCOQUJW-UHFFFAOYSA-N 2-[4-[4-[(4-chloro-3-fluorophenyl)carbamoyl]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NC=2C=C(F)C(Cl)=CC=2)C=C1 KUKXAEMVCOQUJW-UHFFFAOYSA-N 0.000 description 1
- YFWSUBNOKZSEFJ-UHFFFAOYSA-N 2-[4-[4-[(4-chlorobenzoyl)amino]phenoxy]-3-[[(4-fluorophenyl)sulfonylamino]methyl]phenyl]acetic acid Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 YFWSUBNOKZSEFJ-UHFFFAOYSA-N 0.000 description 1
- PEZZDBHHHAQANH-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3,5-dimethylphenyl]acetic acid Chemical compound CC1=CC(CC(O)=O)=CC(C)=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 PEZZDBHHHAQANH-UHFFFAOYSA-N 0.000 description 1
- RBZBIJCEGRHONG-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-(4-methylsulfonylphenyl)phenyl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 RBZBIJCEGRHONG-UHFFFAOYSA-N 0.000 description 1
- NBTFNOPLJJLIOL-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-[(pyridine-3-carbonylamino)methyl]phenyl]acetic acid Chemical compound C=1C=CN=CC=1C(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 NBTFNOPLJJLIOL-UHFFFAOYSA-N 0.000 description 1
- UFBCIHJJPVYQHL-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-[[[2-[(4-fluorophenyl)sulfonylamino]acetyl]amino]methyl]phenyl]acetic acid Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)NCC(=O)NCC1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 UFBCIHJJPVYQHL-UHFFFAOYSA-N 0.000 description 1
- OHCMQGQCROEVKM-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-[[methyl(methylsulfonyl)amino]methyl]phenyl]acetic acid Chemical compound CS(=O)(=O)N(C)CC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 OHCMQGQCROEVKM-UHFFFAOYSA-N 0.000 description 1
- XLLQSQSPCLWIEQ-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-cyanophenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 XLLQSQSPCLWIEQ-UHFFFAOYSA-N 0.000 description 1
- IWZJHLCTTLLVPN-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-ethylphenyl]acetic acid Chemical compound CCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 IWZJHLCTTLLVPN-UHFFFAOYSA-N 0.000 description 1
- KFIDIFZVYZWNQI-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-thiophen-2-ylphenyl]acetic acid Chemical compound C=1C=CSC=1C1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 KFIDIFZVYZWNQI-UHFFFAOYSA-N 0.000 description 1
- AFVSFZGYEQJQTC-UHFFFAOYSA-N 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 AFVSFZGYEQJQTC-UHFFFAOYSA-N 0.000 description 1
- VXFWJJJIFUEHHS-UHFFFAOYSA-N 2-[4-[4-[2-(4-fluorophenyl)ethylcarbamoyl]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(F)=CC=2)C=C1 VXFWJJJIFUEHHS-UHFFFAOYSA-N 0.000 description 1
- PFHULMIUFRZOOK-UHFFFAOYSA-N 2-[4-[4-[2-(benzylamino)-2-oxoethyl]phenoxy]-3-(methanesulfonamidomethyl)phenyl]acetic acid Chemical compound CS(=O)(=O)NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1CC(=O)NCC1=CC=CC=C1 PFHULMIUFRZOOK-UHFFFAOYSA-N 0.000 description 1
- ZASJPPYCBQIBPO-UHFFFAOYSA-N 2-[4-[4-[[1-(4-chlorophenyl)cyclopropyl]carbamoyl]phenoxy]-3-cyanophenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NC2(CC2)C=2C=CC(Cl)=CC=2)C=C1 ZASJPPYCBQIBPO-UHFFFAOYSA-N 0.000 description 1
- MCNNHWUAJWKGNJ-UHFFFAOYSA-N 2-[4-[4-[[2-(4-chlorophenyl)cyclopropyl]carbamoyl]phenoxy]-3-cyanophenyl]acetic acid Chemical compound N#CC1=CC(CC(=O)O)=CC=C1OC1=CC=C(C(=O)NC2C(C2)C=2C=CC(Cl)=CC=2)C=C1 MCNNHWUAJWKGNJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- NXWTWYULZRDBSA-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1F NXWTWYULZRDBSA-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- ABUKMOCUMIPDHV-UHFFFAOYSA-N 2-phenoxy-2-phenylacetic acid Chemical class C=1C=CC=CC=1C(C(=O)O)OC1=CC=CC=C1 ABUKMOCUMIPDHV-UHFFFAOYSA-N 0.000 description 1
- RPQWXGVZELKOEU-UHFFFAOYSA-N 3,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1F RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- YSSRLOJIPKHGCY-UHFFFAOYSA-N 3-amino-n-cyclohexyl-3-sulfanylidenepropanamide Chemical compound NC(=S)CC(=O)NC1CCCCC1 YSSRLOJIPKHGCY-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- IFGFGFZDNZQMHM-UHFFFAOYSA-N 4-[2-cyano-4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]phenoxy]benzoic acid Chemical compound N#CC1=CC(CC(=O)OC(C)(C)C)=CC=C1OC1=CC=C(C(O)=O)C=C1 IFGFGFZDNZQMHM-UHFFFAOYSA-N 0.000 description 1
- ACMJJQYSPUPMPN-UHFFFAOYSA-N 4-chloro-3-fluoroaniline Chemical compound NC1=CC=C(Cl)C(F)=C1 ACMJJQYSPUPMPN-UHFFFAOYSA-N 0.000 description 1
- IWLGXPWQZDOMSB-UHFFFAOYSA-N 4-chloro-3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=CC=C1Cl IWLGXPWQZDOMSB-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- VKJXAQYPOTYDLO-UHFFFAOYSA-N 4-methylphenethylamine Chemical compound CC1=CC=C(CCN)C=C1 VKJXAQYPOTYDLO-UHFFFAOYSA-N 0.000 description 1
- ZCIFWRHIEBXBOY-UHFFFAOYSA-N 6-aminonicotinic acid Chemical compound NC1=CC=C(C(O)=O)C=N1 ZCIFWRHIEBXBOY-UHFFFAOYSA-N 0.000 description 1
- 206010066414 Allergy to metals Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UOKSQLHHEOQAPZ-UHFFFAOYSA-N CS(NCc1cc(CC(O)=O)ccc1Oc(cc1)ccc1C(NCCc1ccccc1)=O)(=O)=O Chemical compound CS(NCc1cc(CC(O)=O)ccc1Oc(cc1)ccc1C(NCCc1ccccc1)=O)(=O)=O UOKSQLHHEOQAPZ-UHFFFAOYSA-N 0.000 description 1
- SOKCIIYFIOXWBN-UHFFFAOYSA-N C[n]1c(S(NCc(cc(CC(O)=O)cc2)c2Oc(cc2)ccc2C(NCCc(cc2)ccc2Cl)=O)(=O)=O)cnc1 Chemical compound C[n]1c(S(NCc(cc(CC(O)=O)cc2)c2Oc(cc2)ccc2C(NCCc(cc2)ccc2Cl)=O)(=O)=O)cnc1 SOKCIIYFIOXWBN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 101710155962 Diuretic hormone 2 Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000979190 Homo sapiens Transcription factor MafB Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HSDHWWKJICNYGR-UHFFFAOYSA-N N#Cc1cc(CC(O)=O)ccc1Oc(cc1)ccc1C(NCCc1cc(Cl)ccc1)=O Chemical compound N#Cc1cc(CC(O)=O)ccc1Oc(cc1)ccc1C(NCCc1cc(Cl)ccc1)=O HSDHWWKJICNYGR-UHFFFAOYSA-N 0.000 description 1
- NPHARFSNEMQBSY-UHFFFAOYSA-N NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 Chemical compound NCC1=CC(CC(O)=O)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 NPHARFSNEMQBSY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- JBKKZXMATGLULL-UHFFFAOYSA-N Nc1ccc(CC2CCC2)cc1N Chemical compound Nc1ccc(CC2CCC2)cc1N JBKKZXMATGLULL-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- REYARXKTJBDDLF-UHFFFAOYSA-N OC(Cc(cc1C(F)(F)F)ccc1Oc(cc1)ccc1C(NCCc(cc1)ccc1Cl)=O)=O Chemical compound OC(Cc(cc1C(F)(F)F)ccc1Oc(cc1)ccc1C(NCCc(cc1)ccc1Cl)=O)=O REYARXKTJBDDLF-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010058141 Skin graft rejection Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102100023234 Transcription factor MafB Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- APNSGVMLAYLYCT-UHFFFAOYSA-N isobutyl nitrite Chemical compound CC(C)CON=O APNSGVMLAYLYCT-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JJJSFAGPWHEUBT-UHFFFAOYSA-N methyl 2-(4-hydroxy-3-methoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C(OC)=C1 JJJSFAGPWHEUBT-UHFFFAOYSA-N 0.000 description 1
- LSLVKJITCXJGNL-UHFFFAOYSA-N methyl 2-[4-[2-amino-4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-fluorophenyl]acetate Chemical compound FC1=CC(CC(=O)OC)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1N LSLVKJITCXJGNL-UHFFFAOYSA-N 0.000 description 1
- HWOSAPSPFDPFFO-UHFFFAOYSA-N methyl 2-[4-[4-[(3,4-dichlorobenzoyl)amino]phenoxy]-3-[[(4-fluorophenyl)sulfonylamino]methyl]phenyl]acetate Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)NCC1=CC(CC(=O)OC)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 HWOSAPSPFDPFFO-UHFFFAOYSA-N 0.000 description 1
- YEPVAKTVHWXFDS-UHFFFAOYSA-N methyl 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]-2-nitrophenoxy]-3-fluorophenyl]acetate Chemical compound FC1=CC(CC(=O)OC)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1[N+]([O-])=O YEPVAKTVHWXFDS-UHFFFAOYSA-N 0.000 description 1
- PEKKAWAYFODGNL-UHFFFAOYSA-N methyl 2-[4-hydroxy-3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]acetate Chemical group COC(=O)CC1=CC=C(O)C(CNC(=O)OC(C)(C)C)=C1 PEKKAWAYFODGNL-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- OPMBTSSEEJYFFM-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-2-fluoro-4-hydroxybenzamide Chemical compound FC1=CC(O)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl OPMBTSSEEJYFFM-UHFFFAOYSA-N 0.000 description 1
- FMCQYUFMMODQDM-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-4-(2-cyclopropyl-4-formylphenoxy)benzamide Chemical compound C1=CC(Cl)=CC=C1CCNC(=O)C(C=C1)=CC=C1OC1=CC=C(C=O)C=C1C1CC1 FMCQYUFMMODQDM-UHFFFAOYSA-N 0.000 description 1
- HZEUZMZISXEXPD-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-4-[4-formyl-2-(trifluoromethyl)phenoxy]benzamide Chemical compound FC(F)(F)C1=CC(C=O)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 HZEUZMZISXEXPD-UHFFFAOYSA-N 0.000 description 1
- CRALMWTYCDKSJY-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 CRALMWTYCDKSJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 101150105899 ppiB gene Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PSAYJRPASWETSH-UHFFFAOYSA-N pyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC=N1 PSAYJRPASWETSH-UHFFFAOYSA-N 0.000 description 1
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 1
- VIVPWOMJFLICOZ-UHFFFAOYSA-N pyridine-3-sulfonyl chloride;hydrochloride Chemical compound Cl.ClS(=O)(=O)C1=CC=CN=C1 VIVPWOMJFLICOZ-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ANVVKEIGMQVMCI-UHFFFAOYSA-N tert-butyl 2-(3-cyano-4-fluorophenyl)propanoate Chemical compound CC(C)(C)OC(=O)C(C)C1=CC=C(F)C(C#N)=C1 ANVVKEIGMQVMCI-UHFFFAOYSA-N 0.000 description 1
- NNGDLOYUAYPSNM-UHFFFAOYSA-N tert-butyl 2-(4-hydroxyphenyl)acetate Chemical compound CC(C)(C)OC(=O)CC1=CC=C(O)C=C1 NNGDLOYUAYPSNM-UHFFFAOYSA-N 0.000 description 1
- QBKCOFCADBOGKZ-UHFFFAOYSA-N tert-butyl 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-[(pyridine-3-carbonylamino)methyl]phenyl]acetate Chemical compound C=1C=CN=CC=1C(=O)NCC1=CC(CC(=O)OC(C)(C)C)=CC=C1OC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1 QBKCOFCADBOGKZ-UHFFFAOYSA-N 0.000 description 1
- WHBWXTYYFGUTFN-UHFFFAOYSA-N tert-butyl 2-[4-[4-[2-(4-chlorophenyl)ethylcarbamoyl]phenoxy]-3-cyanophenyl]acetate Chemical compound N#CC1=CC(CC(=O)OC(C)(C)C)=CC=C1OC1=CC=C(C(=O)NCCC=2C=CC(Cl)=CC=2)C=C1 WHBWXTYYFGUTFN-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- QXXJGZQLPDQOPF-UHFFFAOYSA-M zinc;benzene;iodide Chemical compound I[Zn+].C1=CC=[C-]C=C1 QXXJGZQLPDQOPF-UHFFFAOYSA-M 0.000 description 1
- NMLXKNNXODLJIN-UHFFFAOYSA-M zinc;carbanide;chloride Chemical compound [CH3-].[Zn+]Cl NMLXKNNXODLJIN-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to a process for making the compounds and to the use of the compounds in therapy. More particularly it relates to certain 4-substituted phenoxyphenylace ⁇ c acid derivatives useful in the treatment and prevention of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D 2 (PGD 2 ).
- PPD 2 prostaglandin D 2
- the present invention provides a compound of general formula (1):
- R' is Ar'-L'-W-l ⁇ ;
- 0008] L 2 is -(CR 0 RV; [0009] W is -CONR 38 - or -NR 3b CO-; [0010] R 3a and R 3b are each H or methyl;
- each R ⁇ R b , R c and R d is independently H, F, OH, methyl or cyclopropyl, or R° and R b or
- R c and R d together with the carbon to which they are attached form a cyclopropyl ring
- Ar 1 is phenyl or naphthyl, each of which is unsubstituted or substituted with one or more substituents selected independently from F, Cl, CN, CF 3 , CHF 2 , CH 2 F, SF 5 , methyl, ethyl, cyclopropyl, t-butyl or OMc, or Ar 1 is 1,2,3,4-tctrahydronaphthyl which is unsubstituted or substituted by mcthoxy,
- R 2 is H, Ci-C 6 alkyl, a residue of an amino acid or dipeptide, or CHR e (CH 2 ) q R f ;
- R c is H, methyl or ethyl
- R f is NR 8 R h in which R 8 and R h each independently represents a hydrogen atom or a Ci-
- R 4 " and R 4b arc each H or methyl
- R 5 is Ci-C 6 alkyl, CpC 6 alkoxy, C 3 -C 6 cycloalkyl, hetAr 1 , or Ar 2 ;
- R 6 is C 1 -C 6 alkyl, NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , Ar 3 , or hetAr;
- hetAr 1 is a 6 membered hetcroaryl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom and a group of formula -NR 5a R 5b in which each of R 5a and R 5b independently represents a hydrogen atom or a (1 -4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or morpholino group;
- hetAr 2 is a 5-6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from C 1 -C4 alkyl;
- Ar 2 is phenyl which is unsubstituled or substituted with one or more groups independently selected from a halogen atom, CN, SF 5 , cyclopropyl, a Ci-C 4 alkyl group, a C 1 -C4 alkoxy group and a fluoroCrC.4 alkyl group;
- Ar 3 is as defined for Ar 2 ;
- R 7 and R 8 are independently H, methyl, or F;
- R 9 is H or methyl
- R 10 is H or F.
- the compound of Formula I has the Formula Ia
- R 1 is Ar 1 -L 1 -W-L 2 -;
- L 2 is -(CR c R d ) mS
- W is -CONR 3 ⁇ - or -NR 3b CO-;
- R 3 " and R 3b are each H or methyl
- n and m arc independently 0, 1 or 2;
- each R 0 , R b , R c and R d is independently H, F, methyl or cyclopropyl, or R" and R b or R c and R d together with the carbon to which they are attached form a cyclopropyl ring;
- Ar 1 is phenyl or naphthyl, each of which is unsubstituted or substituted with one or more substituents selected independently from F, Cl, CN, CF 3 , CHF 2 , CH 2 F, SF 5 , methyl, ethyl, cyclopropyl, provided that when Ar 1 is naphthyl then n is 0;
- R 2 is H, Ci-C 6 alkyl, a residue of an amino acid or dipeptide, or CHR c (CH 2 ) q R f ; [0041] q is 1 to 6; [0042] R c is H, methyl or ethyl;
- R f is NR B R h in which R 8 and R h each independently represents a hydrogen atom or a Ci- C A alkyl group, or R g and R h together with the nitrogen atom to which they are attached form a 5-6 membercd heterocyclic ring optionally containing a second ring heteroatom selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from CpC ⁇ alkyl;
- R 4a and R 4b arc each H or methyl
- R 5 is Ci-C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, hctAr 1 , or Ar 2 ; 10047] R 6 is C 1 -C 6 alkyl, NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyi) 2 , Ar 3 , or hetAr 2 ; 4
- hetAr 1 is a 6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom and a group of formula -NR 5a R 5b in which each of R 5a and R Sb independently represents a hydrogen atom or a (1-4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or morpholino group;
- hctAr 2 is a 5-6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from C 1 -C4 alkyl;
- Ar 2 is phenyl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom, CN, SF 5 , cyclopropyl, a C 1 -C 4 alkyl group, a Ci-C 4 alkoxy group and a fluoroCi-C4 alkyl group;
- Ar 3 is as defined for Ar 2 ;
- R 7 and R 8 are independently H, methyl.
- Compounds according to the present invention have been found to be DF2 modulators and are useful in the treatment of immunologic diseases such as asthma and allergic inflammation.
- certain compounds according to the invention may contain one or more centers of asymmetry and may therefore be prepared and isolated in a mixture of isomers such as a racemic mixture, or in an enantiomerically pure form.
- the compounds of Formula I include pharmaceutically acceptable salts thereof.
- the compounds of Formula 1 also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating cnantiomers of compounds of Formula I.
- halogen as used herein includes F, Cl, Br and I.
- CpC 4 alkyl and C)-C 6 alkyl refer to a saturated linear or branchcd-chain monovalent hydrocarbon radical of one to four or one to six carbon atoms, respectively.
- alkyl groups include, but are not limited to, methyl, ethyl, 1-propyl,
- heteroaryl refers to a monovalent aromatic radical of a 5-, 6-, or 7-membercd ring.
- heteroaryl groups include, but are not limited to, pyridinyl, 5 imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, and pyrrolyl.
- fluoroCi-C 4 alkyl refers to a Ci-C 4 alkyl group wherein one or more of the hydrogens is replaced by a fluorine atom. Examples include CF 3 , CH 2 F, CHF 2 ,
- Ci-C 6 alkoxy refers to a Ci-C 6 alkyloxy group.
- exemplary alkoxy groups include mcthoxy, ethoxy, propoxy, isopropoxy, butoxy. t-butoxy, and isobutoxy.
- W is -CONR 3 "-.
- An example of a particular value for K u is hydrogen.
- W is -NR 3h CO-.
- R 3h is hydrogen.
- R 3b is methyl. Examples of particular values for W arc CONH, NHCO and N(CH 3 )CO.
- L 1 is -(CR a R b ) n -. Examples of particular values for n are 0, 1 and 2.
- L 1 is a bond
- L 1 is -(CR°R b ).
- R° and R b are hydrogen.
- R° is OH.
- R° and R b together with the carbon atom to which are attached form a cyclopropylidine ring.
- L 1 is -(CR°R b ) 2 .
- R" and R b are hydrogen.
- R" and R b together with the carbon atom to which are attached form a cyclopropylidine ring. In certain embodiments, R" and R b are attached to the same carbon. In other embodiments, R" and R b arc attached to different carbon atoms.
- L 1 examples of particular values for L 1 are a bond, -CH 2 -, -CH 2 CH 2 - and cyclopropylidcneCH 2 .
- L 1 includes CH(OH)CH 2 .
- V include cyclopropylidine groups, which can be represented by the following structures:
- L 1 is -O(CR°R b )-.
- An exemplary embodiment is -OCH 2 -.
- examples of particular values for m are 0 and 1.
- examples of particular values for L 2 are a bond and -CH 2 -.
- the sum of m and n is 0, 1 and 2. Particular mention is made of compounds in which the sum of m and n is 0 or 2.
- Examples of values for -L'-W-l ⁇ include -CONH-, -CH 2 CONH-, -CH 2 CH 2 CONH-,
- Ar 1 is a naphthyl group or a phenyl group that is substituted by one or two substituents independently selected from F, Cl CF 3 , OMe, Me, and t-Bu.
- Ar 1 is a naphthyl group or a phenyl group that is unsubstituted or substituted by one or tvvo substituents selected independently from F, Cl and CF 3 .
- Ar 1 is a naphthyl group or a phenyl group that is substituted by one or two substituents independently selected from OMe, Me, and t-Bu.
- Ar' is 1,2,3,4-tetrahydronaphthyl which is unsubstituted or substituted with OMe.
- A is selected from the structures:
- Ar 1 examples of particular values for Ar 1 are naphthyl, phenyl, 4-fluorophenyl, 3,4- di fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-chloro-3- fluorophcnyl, 3-chloro-4-fIuorophcnyl, 4-trifluoromethylphcnyl, 3-fluoro-4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2,6-dichlorophenyl, 2,4-dichlorophenyl, 3-methoxyphcnyl, 4- ⁇ crtbulylphenyl, 3-fluorophenyl, 4-methylphenyI, l,2,3,4-tetrahydronaphth-2-yl and 6-methoxy- l,2,3,4-tetrahydronaphth-2-yl.
- Ar 1 is selected from naphthyl, phenyl, 4-fluorophenyl, 3,4- di fluorophenyl, 2-chlorophcnyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-chloro-3- fluorophcnyl, 3-chloro-4-fluorophenyl, 4-lrifluoromethylphenyl and 3-fluoro-4- tri fluoromethy (phenyl .
- Ar 1 is selected from 3-trifluoromethylphenyl, 2,6- dichlorophenyl, 2,4-dichlorophenyl, 3-methoxyphenyI, 4-methoxyphenyl, 4-tertbutylphenyl, 3-fluorophenyl and 4-methylphenyl, and l,2,3,4-tetrahydronaphth-2-yl and 6-methoxy- 1,2,3,4- tetrahydronaphth-2-yl.
- A is CN.
- A is H. 7
- A is selected from F, Br and Cl.
- A is selected from (l-4C)alkyl. Particular examples include methyl and ethyl.
- A is cyclopropyl
- A is selected from CH 2 NH 2 , CH 2 NH(I-C alkyl), and CH 2 N(MC alkyl) 2 .
- Particular examples include CH 2 NH 2 and CH 2 NMe 2 .
- A is thienyl. In a particular embodiment, A is 2-lhienyI.
- A is phenyl which is unsubstitutcd or substituted with SO 2 Me.
- Particular examples include phenyl, 3-mcthylsulfonyIphenyI, and 4-mcthylsulfonylphenyl.
- A is C H 2 N R 411 C( 3 O)R 5 .
- An example of a particular value for R 4 * is hydrogen.
- R 5 is hetAr 1 .
- An example of a particular value for a heteroaryl group represented by hetAr 1 is a pyridyl group. Examples of optional subs ⁇ tucnts on the heteroaryl group are NH 2 , Cl, and pyrrolidinyl.
- R 5 is Ci-Ce alkyl; CpC 6 alkoxy; C 3 -C 6 cycloalkyl; pyridyl which is unsubstituted or substituted by a halogen atom or a group of formula -NR 5 "R Sh in which each of
- R 5 " and R 5b independently represents a hydrogen atom or a (1 -4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or morpholino group; or a phenyl group that is unsubstiluted or substituted by one or two halogen atoms.
- R 5 examples of particular values for R 5 are methyl, mclhoxy, cyclohcxyl, pyrid-2-yl, pyrid-
- R 5 6-dimethylaminopyrid-3-yl.
- A is CH 2 NR*SO 2 R ⁇ .
- An example of a particular value for R 4b is hydrogen.
- K 6 is hetAr 2 .
- Examples of particular values for a heteroaryl group represented by hetAr arc an imidazolyl and a pyridyl group.
- Examples for optional substituents on the heteroaryl group are Ci -C 4 alkyl, for example methyl.
- R 6 is Ci-C 6 alkyl, NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , a phenyl group that is unsubstituted or substituted by one or two halogen atoms, pyridyl or imidazolyl that is unsubstituled or substituted with a C1-C 3 alkyl group.
- R 6 examples of particular values for R 6 arc methyl, dimethylamino, 4-fluorophenyl, 2,4- dichlorophenyl, pyrid-3-yl and l-methylimidazol-5-yl.
- An additional example of R 6 is pyrid-4-yl.
- Examples of particular values for A are acetamidomcthyl, cyclohexylamidomethyl, methoxycarbonylaminomcthyl, picolinamidomethyl, nicotinamidomethyl, isonicotinamidomethyl, 6- chloropyrid-3-ylamidomethyl, 6-aminopyrid-3-ylamidomethyl, 6-pyrroIidin-l-ylpyrid-3- ylamidomelhyl, 4-fluorobenzamidometh ⁇ i, methylsulfonamidomethyl, N,N- dimcthylsulfamoylamino, 4-fluorophcnylsulfonamidomethyl, 2,4-dichlorophenyl- sulfonamidomcthyl, l-methylimidazol-5-ylsulfonamidomethyl and pyrid-3-ylsulfonamidomethyl, which can be represented by the following
- Particular values for A also include 6-dimeuiylamtnopyrid-3-ylamidomethyI, 2-(4-fluorophenylsulfonamido)acetamidomethyl, dimethylaminomethyl and (N- methylmethylsulfonamido)methyl, which can be represented by the following structures, respectively:
- R 2 when it represents a CpC 6 alkyl group examples are methyl, ethyl, propyl, isopropyl and t-butyl.
- R 2 is CHR c (CH 2 ) q R r .
- values for R c are hydrogen and methyl.
- R r is di(l-4C)alkylamino, morpholino, or piperazinyl optionally substituted with (l-4C)alkyl.
- Examples of particular values for R r are dimethylamino, diethylamino, morpholino, piperazinyl and 1-mcthylpiperazinyl. Additional examples include NH 2 and NHMe. [00102
- R 2 is hydrogen
- both R 7 and R s are H. In certain embodiments, R 7 is H and R 8 is methyl. In other embodiments, each of R 7 and R s is methyl.
- the present invention provides a process for the preparation a compound of formula (I) or a salt thereof as defined hcreinabove, which comprises:
- R l0 ° is H or F in the presence of a base
- R 8 are independently H or Me, reducing a corresponding compound formula (IV) 10
- E is an electron withdrawing group, in the presence of a base; and if desired removing said electron withdrawing group; or
- the leaving atom or group represented by Z 1 may be, for example, a halogen atom such as a fluorine atom.
- the carboxyl protecting group may be any convenient carboxyl protecting group, for example as described in Greene & Wuts, eds., "Protecting
- carboxyl protecting groups include (l-6C)alkyl groups, such as methyl, ethyl and t-butyl.
- the base may be, for example, an alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate or potassium carbonate, or a tertian' amine, such as triethylamine or N,N-diisopropylethylamine.
- Convenient solvents include amides, sulfoxides and nitriles, such as DMF, DMSO or acetonitrile.
- the reaction can be performed at an elevated temperature, such as in the range of from 50 to 150 0 C.
- the compound of formula (IV) can be reduced by hydrogenation in the presence of a Group VIII metal catalyst, such as Rancy Ni with mcthanol/ammonia.
- the reaction can be conducted at a temperature in the range of from 0 to 100 0 C.
- the dioxoisoindolinyl group can be cleaved using HBr and acetic acid or hydrazine.
- XII in the presence of a base, in which Z 4 represents a leaving atom or group, such as a fluorine atom, and R lx represents an electron withdrawing group convertible into a group R 1 , for example a nitro group that can be reduced to an amino group and then acylated.
- the base may be, for example, an 15 alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate or potassium carbonate.
- Compounds of formula (IX) can be prepared by reacting 4-hydroxyphenylacetic acid with 2-(hydroxymethyl)isoindoline-l,3-dione in the presence of a sulfonic acid, such as methancsulfonic acid, and followed if desired by introducing a protecting group P 3 .
- a sulfonic acid such as methancsulfonic acid
- the leaving atom or group represented by Z 2 and Z 3 may be, for example, a halogen atom such as a fluorine atom.
- the reaction can be performed in the presence of a base, for example a tertiary amine such as diisopropylethylamine or pyridine.
- Convenient solvents include halogcnated hydrocarbons, such as methylene chloride.
- the reaction can be conducted at a temperature in the range of from 0 to 100 0 C.
- the coupling of the compound of formula (VII) with a compound of formula (VlII) may be performed using conventional amide bond formation conditions, for example by reacting an amine with a reactive derivative of a carboxylic acid, for example an acid halidc, such as an acid chloride.
- a reactive derivative of a carboxylic acid for example an acid halidc, such as an acid chloride.
- An example of A 1 when it represents a protected form of A is a group of formula -CH 2 NR 4 P 6 in which P 6 represents an amine protecting group.
- the amine protecting group may be any convenient amine protecting group, for example as described in
- amine protecting groups include acyl and alkoxycarbonyl groups, such as t-butoxycarbonyl
- examples of electron withdrawing groups include NO 2 .
- this group can be removed, if desired, by reducing the nitro group to an amino group using any convenient reducing conditions (for example, Zn and NH 4 Cl) followed by cleavage of the amino group (for example, by treating the amino compound with isobutyl nitrite).
- the base may be, for example, an alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate or potassium carbonate.
- the Z 4 group represents a suitable leaving atom or group, such as a fluorine atom, and R lx represents an electron withdrawing group convertible into a group R 1 , for example a nitro group that can be reduced to an amino group and then acylaled.
- the leaving atom or group represented by Z 5 may be, for example, a halogen atom such as a fluorine atom.
- the base may be, for example, an alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate, or potassium carbonate.
- Convenient solvents include sulfoxides such as DMSO.
- the reaction can be performed at elevated temperatures, ibr example in the range of 50- 100 "C, for example at 85 0 C.
- the carbonyl group can 16 be converted to a carboxyl group by treating the coupling product with methylsulfonyl/methylthiomcthane to provide an intermediate having the formula (XVIII)
- the halide represented by X can be F, Cl or Br.
- Convenient solvents include ethers such as THF or dioxanc.
- Suitable palladium (0) catalysts include Pd(PPIb) 4 and bis(tri-t-butylphosphinc)palladium (0).
- a convenient base when compound (XVI) is reacted with a boronic acid reagent includes DBU. The reaction can be performed at elevated temperatures, for example in the range of 50-100 0 C, for example 60 0 C.
- reaction is conveniently performed in the presence of an amine base, for example pyridine.
- an amine base for example pyridine.
- the reaction is conveniently performed in the presence of a base, for example a hydride such as sodium cyanoborohydride in an alcohol solvent such as methanol.
- a base for example a hydride such as sodium cyanoborohydride in an alcohol solvent such as methanol.
- the reaction is preferably performed in the presence of a catalytic amount of acid, for example acetic acid.
- the reaction is conveniently performed at ambient temperature.
- Compounds which are modulators of DP2 are useful in the treatment of diseases or disorders mediated by PGD 2 , for example, diseases or disorders associated with overproduction or dysregulation Of PGD 2 .
- treatment includes prophylaxis as well as treatment of an existing condition.
- disorders or diseases that may be treated with compounds according to the invention include immunologic diseases. 17
- immunologic diseases include allergic inflammatory diseases, such as asthma, atopic dermatitis, allergic rhinitis, seasonal allergies, food allergies, contact hypersensitivity (e.g., nickel sensitivity), hypcr-cosinophilic syndromes, and allergic conjunctivitis.
- allergic inflammatory diseases such as asthma, atopic dermatitis, allergic rhinitis, seasonal allergies, food allergies, contact hypersensitivity (e.g., nickel sensitivity), hypcr-cosinophilic syndromes, and allergic conjunctivitis.
- Additional diseases or disorders which may be treated with the compounds of this invention include inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, ileitis and enteritis, vasculitis, Behcet's syndrome, psoriasis and inflammatory dermatoses such as dermatitis, eczema, urticaria, viral cutaneous pathologies such as those derived from human papillomavirus, HIV or RLV infection, bacterial, fungal and other parasital cutaneous pathologies, and cutaneous lupus erythematosus, respiratory allergic diseases such as persensitivity lung diseases, chronic obstructive pulmonary disease and the like, autoimmune diseases, such as arthritis (including rheumatoid and psoriatic), systemic lupus erythematosus, type I diabetes, myasthenia gravis, multiple sclerosis, Graves' disease, glomerulonephritis and the like, graft rejection (including allograft rejection
- another aspect of this invention provides a method of treating diseases or medical conditions in a mammal mediated by PGD2, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to treat or prevent said disorder.
- the phrase "effective amount” means an amount of compound that, when administered to a mammal in need of such treatment, is sufficient to (i) treat or prevent a particular disease, condition, or disorder mediated by PGD2, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein. 18
- the amount of a compound of Formula 1 that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
- the term "mammal” refers to a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.
- This invention also provides compounds of Formula I for use in the treatment of PGD2- mediatcd conditions.
- An additional aspect of the invention is the use of a compound of Formula I in the preparation of a medicament for therapy, such as for the treatment or prevention PGD2 -mediated conditions.
- the compounds of the present invention can be used in combination with one or more additional drugs, for example an anti-inflammatory compound that works by a different mechanism of action.
- the compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rcclally or orally), the nose, lungs, musculature or vasculature or transdermally.
- the compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc.
- Such compositions ma)' contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention.
- the present invention provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined hereinabove.
- the pharmaceutical composition includes the compound of formula (I) together with a pharmaceutically acceptable diluent or carrier.
- the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in therapy.
- the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to (real an immunologic disorder, as defined hereinabove. 19
- the coding sequence of human DP2 was introduced into the human Leukemic cell line K562 by electroporation and stable clones expressing DP2 were obtained by limiting dilution followed by cell surface staining with a rat monoclonal antibody specific for human DP2.
- Membranes were prepared from one of these DP2 expressing clones and used to determine the ability of the compounds of the present invention to inhibit binding of prostaglandin D2 (PGD2) to its receptor DP2 by the following procedure.
- Membranes (1.25 Og ⁇ vell) were mixed with 3 H- labeled PGD 2 and various concentrations of test compounds in 150 ⁇ L of binding buffer (50 mM Tris-HCl, pH 7.4, 40 mM MgCl 3 , 0.1% bovine serum albumin, 0.1% NaN 3 ) in 96-well U-bottom polypropylene plates. After incubation for 60 minutes at room temperature, the assay was transferred to a filtration plate (#MAFB; Milliporc Corporation, Bedford, MA), and washed three times with binding buffer. Radioactivity was measured by a scintillation counter (TopCount; PerkinElmer Life Sciences, Boston, MA).
- binding buffer 50 mM Tris-HCl, pH 7.4, 40 mM MgCl 3 , 0.1% bovine serum albumin, 0.1% NaN 3
- Nonspecific binding was determined by incubations in the presence of 1 ⁇ M unlabeled PGD 2 or 5 DM of a known DP2 antagonist.
- IC 50 values for inhibition of binding are determined for each compound tested from the inflexion point of a standard 4-parameter logistical curve fitted to the values obtained. All compounds disclosed herein had IC 50 values less than 1 micromolar. 20
- Step A 2-(4-hydrox> ⁇ henyl)acetic acid (7.0 g, 46 mmol) was diluted with methane sulfonic acid (100 mL) and cooled to -10 0 C.
- Step B The product of step A (6.7 g, 22 mmol) was diluted with HBr (21 g, 258 mmol) and acetic acid (20 mL). The reaction mixture was heated to reflux and stirred overnight. The reaction mixture was then cooled to 0 0 C and was neutralized with solid NaOH pellets to pH ⁇ 10, affording a solution of 2-(3-(aminomethyl)-4-hydroxyphenyI)acetic acid which was used in the next step without further purification.
- Step C To 2-(3-(aminomethyl)-4-hydroxyphenyl)acctic acid (3.9 g, 21.5 mmol) was added BOC2O (5.40 g, 24.8 mmol) in 30 mL of dioxane. After stirring for 4 hours, the reaction was diluted with ethyl acetate and IN HCl. The organic layer was dried over MgSO 4 and concentrated. The solid was taken up in minimal methylene chloride, filtered and rinsed with methylene chloride. The filtrate was concentrated to yield 3.0 g of 2-(3-((tert-butoxycarbonyl)aminomethyl)-4- hydroxyphenyl)acctic acid as a white foam.
- Step D 2-(3-((tert-Butoxycarbonyl)aminomethyl)-4-hydroxyphenyl)acetic acid (1.6 g, 5.69 mmol) was diluted with THF ( 10 mL) and methanol (5 mL) followed by the addition of TMSCHN 2 (14.2 mL, 28.4 mmol) dropwise. The reaction mixture was stirred for 30 minutes and then diluted with ethyl acetate and water. The layers were separated and the organic layer was dried 21 over MgSQi, filtered and concentrated. The material was purified using a biotagc 4OS cartridge eluting with hexanes:ethyl acetate (4: 1) yield 860 nig of clear oil that later solidified to methyl 2-(3-
- Step E Methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-hydrox ⁇ 'phenyl)acetate (200 mg, 0.677 mmol) was diluted with ACN (2 rnL) followed by the addition of K 2 CO 3 (206 mg, 1.49 mmol) and l-fluoro-4-nitrobenzene (0.103 mL, 0.948 mmol). The reaction mixture was heated to reflux (at about 82 0 C) and stirred for 5 hours. The reaction mixture was then diluted with ethyl acetate and water. The layers were separated and the organic layer was dried over MgSO.4, filtered and concentrated. The material was purified using a biotage 4OS eluting with hcxancs/cthyl acetate
- Step F Methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-(4-ni ⁇ Ophenoxy) phenyOacetate (242 mg, 0.581 mmol) was diluted with THF (3 mL) followed by the addition of Zn dust (38.0 mg, 0.581 mmol). About 2 mL of saturated ammonium chloride was added dropwise.
- reaction mixture was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the organic layer was dried over
- Step G Methyl 2-(4-(4-aminophenoxy)-3-((tert-butoxycarbonyl)aminomcthyl) phenyOacetate (100 mg, 0.259 mmol) was diluted with methylene chloride (3 mL) followed by the addition of 3,4-dichlorobenzoyl chloride (81.3 mg, 0.388 mmol) and N,N-diisopropylethyl amine
- Step H Methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-(4-(3,4- dichlorobenzamido)phenoxy)phenyl)acetatc (130 mg, 0.232 mmol) was treated with HCl (0.581 mL,
- Step I The product of step H (30 mg, 0.065 mmol) was diluted with methylene chloride
- Step J Methyl 2-(4-(4-(3,4-dichlorobenzamido)phenoxy)-3-((4-fiuorophenyl- sulfonamido)mcthyl)phenyl)acetate (40 mg, 0.065 mmol) was diluted with MeOH (1 mL) followed by the addition of NaOH (0.32 mL, 1.3 mmol). After stirring for I hour, the reaction mixture was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO 4 , filtered and concentrated.
- Step A 4-Aminophenol (1.9 g, 17 mmol) was diluted with DMF (40 mL) followed by the addition of pyridine (0.978) (1.4 mL, 17 mmol) and 3,4-dichlorobenzoyl chloride (3.0 g, 14 mmol) in 5 mL of DMF. After stirring for 12 hours, the reaction mixture was diluted with ethyl acetate and 2N HCl. The aqueous layer was extracted once with ethyl acetate. The organics were combined, washed with water, brine, dried over MgSO 4 , filtered and concentrated onto silica gel.
- the material was purified using a biotage 4OM column eluting with hexanes:cthyl acetate (9: 1) using 2 L and then (60:40) IL to yield 3,4-dichloro-N-(4-hydroxyphenyl)-benzamide ( 1.5 g, 37% yield) as a white solid.
- Step B tert-Butyl 2-(3-cyano-4-fluorophenyl)acetate (2.0 g, 8.5 mmol) and the product of step A (2.9 g, 10 mmol) were diluted with DMSO (22 mL) followed by the addition of potassium carbonate (1.4 g, 10 mmol). The reaction was heated to 125 0 C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate and 10% aqueous sodium carbonate. The layers were separated and the organic layer was washed with 10% aqueous sodium carbonate two more times followed by water and brine. The organic material was dried over MgSO4, filtered and concentrated.
- Step C The product of step B (100 mg, 0.201 mmol) was diluted with 7N ammonia/methanol (10 mL), followed by addition of ethyl acetate (10 mL). Once the material dissolved, Raney Nickel (1.72 mg, 0.0201 mmol) was added and die reaction was purged three times with a balloon of hydrogen.
- Step D The product of step C (0.050 g, 0.997 mmol) was dissolved into I mL of DCM in a small test tube. Pyridine (0. 017 g, 0.219 mmol) and nicotinoyl chloride (0.0195 g, 0.110 mmol) were added, and the reaction mixture was stirred for 12 hours. The reaction mixture was then diluted with methylene chloride and water.
- Step E The product of step D (44 mg ; 0.073 mmol) was diluted with methylene chloride:TFA (1 : 1 ) and stirred for 3 hours. The reaction mixture was concentrated, taken up in ether and sonicated. The solid was filtered, rinsed with ether and dried under vacuum to yield the title compound (35 mg, 88% yield) as white solid.
- 1 H NMR 400 MHz, CDCI 3 /CD 3 OD) 8.75 (m, IH), 8.65 (m, IH), 8.15 (m, IH), 8.
- Step A tert-Butyl 2-(3-cyano-4-fluorophenyl)acetatc (2.6 g, 11.1 mmol) and methyl 4- hydroxybenzoate (3.36 g, 22.1 mmol) were diluted with DMSO (22 mL) followed by the addition of potassium carbonate (1.83 g, 13.3 mmol). The reaction mixture was heated to 125 0 C and stirred for 5 hours. The reaction mixture was diluted with ethyl acetate and 10% aqueous sodium carbonate. The layers were separated and the organic layer was washed with 10% aqueous sodium carbonate two more times followed by water and brine. The organic material was dried over MgSO 4 , filtered and concentrated.
- Step B The product of step A (2.5 g, 6.80 mmol) was diluted with TN ammonia/niethanol (30 mL) followed by the addition of Raney Nickel (0.0583 g, 0.680 mmol). The reaction mixture was purged three times with hydrogen and stirred for 12 hours. The reaction mixture was then filtered through a GF/F filter and concentrated.
- Step C The product of step B ( 1.87 g, 5.03 mmol) was diluted with methylene chloride (2 mL) followed by the addition of pyridine (0.489 mL, 6.04 mmol) and methanesulfonyl chloride (0.779 mL, 10.1 mmol).
- Step D The product of step C (900 mg, 2.00 mmol) was diluted with dioxane (10 mL) followed by the addition of LiOH-H 2 O (126 mg, 3.00 mmol) dissolved in water (2 mL). After stirring for 12 hours, the reaction mixture was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSU4, filtered and concentrated.
- the material was purified using a biotage 4OM cartridge cluting with methylene chloridc:MeOH (95:5) to yield 4- (4-(2-tert-butox)'-2-oxoethyl)-2-(mcthylsulfonamido-melhyl)phenoxy)bcnzoic acid (710 mg, 81.4% yield) as a clear oil.
- Step E The product of step D (62 mg, 0.14 mmol) was diluted with methylene chloride (1 mL) followed by the addition of oxalyl dichloride (0.093 mL, 0.19 mmol) and 1 drop of DMF. The reaction was stirred for 30 minutes followed by the addition of 3,4-dichlorobenzenamine (46 mg, 0.28 mmol). The reaction was allowed to stir for 1 hour.
- reaction mixture was loaded directly onto a 12i sim and purified on the horizon eluting with methylene chloride:MeOH (99.5-0.5 to 95:5) to yield 30 mg of tert-butyl 2-(4-(4-((3,4-dichlorophenyl)carbamoyl)phenoxy)-3- (metliylsulfonamidomethyl)phenyl)acetate as a clear oil.
- Step F The product of step E (22 mg, 0.038 mmol) was diluted with methylene chloride (1 mL) followed by the addition of TFA (1 mL). After stirring for 1 hour, the reaction was concentrated, diluted with ether, sonicated and concentrated to yield 2-(4-(4-((3,4- dichlorophenyl)carbamoyl)phenoxy)-3-(metliylsulfonamidomethyl)phenyl)acetic acid (15 mg, 75% 30 yield) as a white solid.
- Step A 2-(3-Chloro-4-hydroxyphenyI)acetic acid (5.0 g, 26.8 mmol) was dissolved in 30 mL of MeOH and H 2 SO 4 (0.744 ml, 13.4 mmol) was added dropwise at ambient temperature. The reaction was refluxed for four hours and then concentrated in vacuo. The residue was diluted with 150 mL of EtOAc and washed sequentially with saturated NaHCOj, water, and brine, dried over H2SO4, and concentrated in vacuo to provide methyl 2-(3-chloro-4-hydroxyphcnyl)acetate (5.16 g, 96.0% yield) as a semi-opaque thick oil.
- Step B Methyl 2-(3-chloro-4-hydroxyphcnyl)acetatc (177 mg, 0.885 mmol) was diluted with DMSO (3 mL) followed by the addition of K 2 CO 3 ( 122 mg, 0.885 mmol) and N-(4- chlorophcncthyl)-4-chloro-3-nitrobcnzamide (300 mg, 0.885 mmol) (synthesized in step C). The reaction was heated to 85 0 C and stirred for 12 hours. The reaction was cooled, diluted with DCM and washed with 10% aq. sodium carbonate, water and brine. The layers were separated and the organic layer was dried over H 2 SO4, filtered and concentrated.
- Step C 2-(4-Chlorophenyl)ethanamine (2.3 ml, 16 mmol) was diluted with DCM (40 niL) followed by the addition of DlEA (2.9 ml, 16 mmol) and 4-chloro-3-nitrobenzoyl chloride (3.0 g, 14 mmol) in 10 mL of DCM. After stirring for 30 minutes the reaction was loaded directly onto a biotage 4OM cartridge and elutcd with hexanes:ethyl acetate (2: 1) to yield N-(4-chlorophenethyI)-4- chloro-3-nitrobenzamide (4.0 g, 86% yield) as a white solid.
- Step D Methyl 2-(4-(4-((4-chlorophenethyl)carbamwl)-2-nilrophenoxy)-3- chlorophenyOacetatc (1 10 mg, 0.219 mmol) was diluted with THF ( I mL) followed by the addition of Zn dust (14.3 mg, 0.219 mmol) and saturated NH 4 CI (1 mL). After stirring for 1 hour, the reaction was diluted DCM and 10% aq. sodium carbonate.
- Step E Isobutyl nitrite (0.0751 ml, 0.634 mmol) was diluted with DMF (1 mL), placed under nitrogen and heated to 60 0 C.
- Step F Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-chlorophenyl)acetate (33 mg, 0.0720 mmol) was diluted with THF (500 ⁇ L) followed by the addition NaOH (0.144 ml, 0.720 mmol) and 100 ⁇ L of water. After stirring for 2 hours, the reaction was diluted with DCM and 2N HCI.
- Step A To a stirred solution of diisopropylaminc (357 ⁇ l, 2.55mmol) in THF (3 ml) at - 78 0 C was added n-butyllithium (2.5M in hcxancs, 1.02 ml, 2.55 mmol). The reaction was stirred for 30 minutes after which time a solution of the acetate (500 mg, 2.13 mmol) in THF (3.5 ml) was added dropwise and stirred for 20 minutes at -78 0 C, then warmed to 0 0 C. MeI (133 ⁇ l, 2.13 mmol) was added and the reaction stirred for an additional 30 minutes.
- Step B To a stirred solution of 4-aminophenol (2.50 g, 22.9 mmol) in DMF (55 ml) was added pyridine (1.85 ml, 22.9 mmol) followed by 3,4-dichlorobenzoyl chloride (4.0 g, 19.1 mmol) in DMF (7 ml). The reaction stirred at ambient temperature overnight, then diluted with 2M HCl and EtOAc. The aqueous layer was then extracted with EtOAc and the combined organics washed with brine and dried over MgSO 4 . The residue was purified on the Biotage Horizon (65+M 5% to 75% B:EtOAc, 51 ml-2448 ml).
- Step C To a stirred solution of tert-butyl 2-(3-cyano-4-fluorophenyl)propanoate (360mg, 1.44mmol) from Step A and 3,4-dichloro-N-(4-hydroxyphenyl)benzamide (488 mg, l.73mmol) from Step B in DMSO (4ml) was added K 2 CO 3 (240 mg, 1.73 mmol). The reaction was stirred at 125 °C overnight, then cooled to ambient temperature and diluted with EtOAc and 10% aqueous sodium carbonate.
- Step D To a stirred solution of tert-butyl 2-(3-cyano-4-(4-(3,4- dichlorobcnzamido)phenoxy)phenyl)propanoate (25 mg, 0.049 mmol) in DCM ( I ml) was added TFA (250 ⁇ l). The reaction was stirred at ambient temperature for 4 hours and then concentrated. The crude product was purified via preparative TLC (5%MeOH/DCM) to give 2-(3-cyano-4-(4-(3,4- 40 dichlorobenzamido)phcnoxy)phcnyl)propanoic acid (0.0174 g, 0.0382 mmol, 78%).
- Step A To a stirred solution of NaH (60% in oil, 195 mg, 4.88 mmol) in DMF (10 ml) at O 0 C was added a solution of tert-butyl 2-(3-cyano-4-fluorophenyl)acetate (500 mg, 2.125 mmol) and McI (330 ⁇ l, 5.31mmol) in DMF (1 ml) dropwise. The reaction was warmed to ambient temperature, stirred overnight, and then diluted with IN HCl and EtOAc.
- Step B 2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(me ⁇ ylsulfonamidomethyl) phenyl)-2-methylpropanoic acid was prepared from tert-butyl 2-(3-cyano-4-fluorophenyl)-2 ⁇ methylpropanoate by the method of Example 35 substituting tert-butyl 2-(3-cyano-4- fluorophenyl)propanoatc in Step B with tert-butyl 2-(3-cyano-4-fluorophcnyl)-2-mcthylpropanoate and following steps B,C and F of Example 14.
- Step A 2-(4-hydroxyphenyl)acetic acid ( 1.0 g, 6.57 mmol) was diluted with THF (4 mL) followed by the addition of Reactant 2 (2.63 g, 13.1 mmol). The reaction was stirred for hours 12 hours. The reaction was filtered and loaded directly onto a biolage 4OM cartridge eluting with hexancsxthyl acetate (3:1) to yield tert-butyl 2-(4-hydroxyphenyl)acctate (800 mg, 58.4% yield) as a clear oil that later solidified to a white solid.
- Step B 2-(4-chlorophenyl)ethanamine (0.321 ml, 2.27 mmol) was diluted with DCM (10 mL) followed by the addition of DIEA (d 0.742) (0.395 ml, 2.27 mmol) and 4-fluorobenzoyl chloride (0.231 ml, 1.89 mmol). After stirring for 30 minutes the reaction was loaded directly onto a biotage 4OS cartridge and eluted with hexanes:ethyl acetate (2: 1 ) to yield N-(4-chlorophenethyl)-4- fluorobenzamide (393 nig, 74.8% yield) as a white solid.
- Step C Tert-butyl 2-(4-hydroxyphenyl)acetate (200 mg, 0.960 mmol) was diluted with DMSO (4 mL) followed by the addition of K 2 CO 3 ( 133 mg, 0.960 mmol) and N-(4- ch!orophenethyl)-4-fluorobcnzamide (267 mg, 0.960 mmol). The reaction was stirred at 85 0 C overnight, and then stirred at 138 0 C for 12 hours. The reaction was cooled to ambient temperature, diluted with DCM and 10% aq. sodium carbonate. The layers were separated and the organic layer was dried over MgSO4, filtered and concentrated.
- Step D Tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyI)phenoxy)phenyl)acetate (20 mg, 0.043 mmol) was diluted with DCM (1 mL) followed by the addition of TFA (1 mL).
- Step A 2-(3-Fluoro-4-hydroxyphenyl)acetic acid (1.0 g, 5.88 mmol) was diluted with THF:McOH (3: 1) (10 mL) followed by the addition Of TMSCHN 2 (5.88 ml, 11.8 mmol). After 44 stirring for 1 hour, the reaction was quenched with 2N HCl and diluted with DCM. The layers were separated and the organic layer was dried over MgSO 4 , filtered and concentrated.
- the material was purified by silica gel chromatography, cluting with hexanes:cthyl acetate (2: 1) to yield methyl 2-(3- fluoro-4-hydroxyphenyl)acetate (700 mg, 64.7% yield) as a clear oil.
- Step B 2-(4-Chlorophenyl)ethanamine (2.3 ml, 16 mmol) was diluted with DCM (40 niL) followed by the addition of DIEA (2.9 ml, 16 mmol) and 4-chloro-3-nitrobenzoyI chloride (3.0 g, 14 mmol) dropwise in 10 mL of DCM. After stirring for 30 minutes the reaction was loaded directly onto a silica gel column and eluted with hcxancsxthyl acetate (2: 1) to yield N-(4- chlorophcncthyl)-4-chloro-3-nitrobcnzamide (4.0 g, 86% yield) as a white solid.
- Step C Methyl 2-(3-fluoro-4-hydroxyphenyl)acetate (prepared in Step A; 163 mg, 0.885 mmol) was diluted with DMSO (3 mL) followed by the addition of K 2 CO 3 ( 122 mg, 0.885 mmol) and N-(4-chlorophenethyl)-4-chloro-3-nilrobenzamide (prepared in Step B; 300 mg, 0.885 mmol). The reaction was stirred at 8O 0 C for 12 hours. The reaction was cooled, diluted with DCM and washed with 10% aq. sodium carbonate, water and brine. The layers were separated and the organic layer was dried over MgSO 4 , filtered and concentrated.
- Step D Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-nitrophenoxy)-3- fluorophenyl)acetate (100 mg, 0.205 mmol) was diluted with THF (2 mL) followed by the addition of Zn dust ( 13.4 mg, 0.205 mmol) and saturated aq.
- Step E Isobutyl nitrile (0.060 ml, 0.51 mmol) was diluted with DMF (2 mL), placed under nitrogen and heated to 6O 0 C followed by the addition of methyl 2-(4-(4-((4- chlorophenethyl)carbamoyI)-2-aminophenoxy)-3-fluorophenyl)acetate (93 mg, 0.20 mmol) in 500 ⁇ L of DMF. The reaction was stirred 30 minutes and then cooled. The reaction was diluted with ethyl acetate and washed with 2N HCI and saturated sodium bicarbonate. The layers were separated and the organic layer was dried over MgSO 4 , filtered and concentrated.
- Step F Methyl 2-(4-(4-((4-chlorophencthyl)carbamoyl)phenoxy)-3- fluorophenyl)acetate (32 mg, 0.072 mmol) was diluted with dioxane ( 1 mL) followed by the addition of NaOH (0.072 ml, 0.36 mmol) and 200 ⁇ L of water.
- Step A A flask was charged with tert-bulyl 2-(3-cyano-4-fluorophenyl)acetate (9.410 g, 40.00 mmol), methyl 4-hydroxybenzoate (7.303 g, 48.00 mmol), K 3 CO 3 (6.634 g, 48.00 mmol), and DMSO (160 mL). The mixture was heated to 90 0 C under a nitrogen atmosphere for 17 hours. The mixture was cooled to ambient temperature and poured into a mixture of EtOAc (250 mL) and 10% K 2 CO 3 solution (250 mL). The resulting insoluble residue was dissolved in water and added to the EtOAc-aqueous mixture. The mixture was stirred for 1 hour and layers were separated.
- Step B Methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoate (1 1.60 g, 31.57 mmol) was dissolved in dioxane (160 mL) and the solution was cooled to 10 0 C in an ice bath. LiOH-H 2 O, IM (37.89 ml, 37.89 mmol) was added to the solution and the mixture was stirred at ambient temperature for 5 hours. The mixture was diluted with 2N HCl ( 10OmL) and CH 2 Cb (200 mL). Layers were separated and aqueous layer was extracted with CH 2 Cl 2 .
- Step C To 4-(4-(2-tert-butoxy-2-oxocthyl)-2-cyanophenoxy)bcnzoic acid (0.34 g, 0.962 mmol), 2-(4-chlorophenyl)ethanamine (0.165 g, 1.06 mmol) in DMF (5 ml) was added diisopropylamine (0.200 ml, 1.15 mmol) and HBTU (0.149 g, 1.15 mmol). The reaction was stirred 46 al ambient temperature for 90 minutes. The reaction was diluted with water and the product extracted into ethyl acetate.
- Step D To tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3- cyanophenyl)acetate (0.40 g, 85%) as a white solid after column chromatography.
- Step D To tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3- cyanophenyOacetatc (4.40 g, 8.96 mmol) in DCM (20 ml) was treated with TFA (20 ml). After stirring for 2 hours.
- the reaction mixture was concentrated and the crude material was purified by silica gel chromatography using a gradient of 0.5% McOH/DCM containing 0.5% AcOH to 10% McOH/DCM containing 0.5% AcOH to provide 2-(4-(4-((4-chlorophencthyl)carbamoyl)phcnoxy)- 3-cyanophcnyl)acctic acid (3.30 g, 84.7% yield).
- Step A N-(4-chlorophenethyl)-4-hydroxybenzamide ( 1.5 g, 5.4 mmol) was diluted with DMSO (15 mL) followed by the addition of K 2 CO 3 (0.89 g, 6.4 mmol) and 3-bromo-4- 47 fluorobenzaldehydc (1.0 g. 4.9 mmol). The reaction was stirred at 85 0 C overnight and then cooled to ambient temperature. The reaction mixture was diluted with ethyl acetate and washed with twice with 10% sodium carbonate, water and brine, and then concentrated.
- Step B N-(4-chlorophenethyl)-4-(2-bromo-4-formylphenox>')benzamide (1.6 g, 3.5 mmol) was diluted with THF (10 mL) followed by the addition of N,N,N- trimcthyl(phenyi)methanaminiurn hydroxide (0.79 ml, 1.7 mmol) and mcthylsulfinyl(rnethylthio)methane (0.87 g, 7.0 mmol). The reaction was stirred at 70 0 C for 2 hours.
- reaction mixture was loaded directly onto a silica gel column and clutcd with DCM:MeOH (98:2) to yield (Z)-N-(4.chlorophcncthyl)-4-(2-bromo-4-(2-(mcthylsulfinyl)-2- (methyithio)vinyl)phenoxy)benzamide (1.9 g, 96% yield).
- Step C (Z)-N-(4-chlorophencthyl)-4-(2-bromo-4-(2-(methylsulfinyl)-2-(methyithio) vinyl)phcnoxy)benzamide (2.0 g, 3.5 mmol) was treated with HCI (8.9 ml, 18 mmol) in ethanol. The reaction was stirred at 70 0 C for 2 hours.
- Step D Ethyl 2-(4-(4-((4-chlorophencthyl)carbamoyl)phcnoxy)-3-bromophenyl)acetate (30 ing, 0.058 mmol) was diluted with dioxane (500 ⁇ L) followed by the addition of NaOH (0.093 ml, 0.46 mmol) and 200 ⁇ L of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl.
- Step A Ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)pheno ⁇ y)-3-bromophenyl)acetate (Example 46 step C ; 30 mg, 0.058 mmol) was diluted with THF ( 1 mL) followed by the addition of bis(tri-t-but ⁇ lphosphinc)palladium (0) (3.0 mg, 0.0058 mmol) and methylzinc chloride (0.087 ml, 0.17 mmol).
- Step B Ethyl 2-(4-(4-((4-chlorophcnetliyl)carbamoyl)phcnoxy)-3-mcthylphenyl)acetate (20 mg, 0.0443 mmol) was diluted with dioxane (500 ⁇ L) followed by the addition of NaOH (0.0885 ml, 0.443 mmol) and 200 ⁇ L of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl.
- Step A Ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (Example 46 step C; 24 mg, 0.046 mmol) was diluted with THF (1 mL) followed by the addition of bis(tri-t-butylphosphine)palladium (0) (2.4 mg, 0.0046 mmol) and 2-thienylzinc bromide (0.23 ml, 0.12 mmol).
- Step B Ethyl 2-(4-(4-((4-chlorophencthyl)carbamoyl)phenoxy)-3-(thiophen-2- yl)phenyl)acctate (20 mg, 0.038 mmol) was diluted with dioxane (500 ⁇ L) followed by the addition of NaOH (0.052 ml, 0.26 mmol) and 200 ⁇ L of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl.
- Step A Ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phcnoxy)-3-bromophcnyl)acctate (Example 46 step C; 24 mg, 0.046 mmol) was diluted with THF (1 mL) followed by the addition of bis(tri-l-butylphosphine)palladium (0) (2.4 mg, 0.0046 mmol) and phenylzinc iodide (0.23 ml, 0.12 mmol).
- Step B Ethyl 2-(6-(4-(4-chlorophenethylcarbamoyl)phcnoxy)biphenyl-3-yl)acetate (10 mg, 0.0195 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.0389 ml, 0.195 mmol) and 200 ⁇ L of water. After stirring for 2 hours, the reaction was diluted with ethyl acetate and 2N HCl.
- Step A Ethyl 2-(4-(4-((4-chlorophcnethyl)carbamoyl)phenox ⁇ )-3-bromophenyI)acetate (Example 46 step C; 100 mg. 0.193 mmol), 3-(mcthanesulfonyl)phenylboronic acid (58.1 mg, 0.290 mmol), K 2 CO 3 (80.2 mg, 0.580 mmol) and Pd(PPh 3 ) 4 (22.4 mg, 0.0193 mmol) were diluted with dioxane (2 mL) and water (1 mL). The reaction was purged three times with nitrogen and stirred at 60 0 C overnight.
- Step B Ethyl 2-(6-(4-(4-chlorophcnethylcarbamoyl)phenoxy)-3'-
- Step A A flask was charged with cyclopropyl magnesium bromide (29.6 ml, 14.8 mmol) and placed under nitrogen. Zinc chloride ( 14.8 ml, 14.8 mmol) was added and the reaction was stirred for 20 minutes. 3-Bromo-4-fluorobenzaldehyde (1.0 g, 4.93 mmol) and bis(tri-t- butylphosphinc)palladium (0) (0.126 g, 0.246 mmol) were diluted in 600 ⁇ L of THF and added to the reaction mixture. After stirring for 4 hours, the reaction was heated to 5O 0 C and stirred overnight. The reaction was cooled and quenched with saturated NH 4 Cl and extracted with DCM.
- Step B N-(4-Chlorophenethyl)-4-hydroxybenzamide (504 mg, 1.83 mmol) was diluted with DMSO (8 mL) and K 2 CO 3 (379 mg, 2.74 mmol) and 3-cyclopropyl-4-fluorobenza!dehyde (300 mg, 1.83 mmol) were added. The reaction was stirred 85 0 C overnight. The reaction was cooled to ambient temperature, diluted with ethyl acetate and washed with twice with 10% sodium carbonate, water and brine, and concentrated.
- Step C N-(4-Chlorophenethyl)-4-(2-cyclopropyl-4-formylphenoxy)benzamide (160 mg, 0.381 mmol) was diluted with THF (3 mL) followed by the addition of N,N,N- trirnethyl(phenyl)mcthanaminium hydroxide (0.0866 ml, 0.191 mmol) and methylsulfinyl(mcthy!thio)rnethane (94.7 mg, 0.762 mmol). The reaction was heated to 70 0 C and stirred for 2 hours.
- Step D (Z)-N-(4-chIorophenetliyl)-4-(2-cyclopropyl-4-(2-(methylsulfinyl)-2-
- Step E Ethyl 2-(4-(4-((4-chlorophcncthyl)carbamoyl)phcnoxy)-3- cyclopropylphenyl)acetate (70 mg, 0.146 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.293 ml, 1 ,46 mmol) and water (300 ⁇ L). After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl.
- Step A Ethyl 2-(4-(4-((4 ⁇ hlorophencthyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (Example 46 step C; 30 mg, 0.058 mmol) was diluted with THF (1 mL) followed by the addition of l, r-bis(diphcnylphosphino)ferroccncdichloropalladium(II) (4.8 mg, 0.0058 mmol) and diethylzinc (0. 13 ml, 0.15 mmol).
- Step B Elhyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-ethylphenyl)acetate (10 mg, 0.0215 mmol) was diluted with dioxanc (500 ⁇ L) followed by the addition of NaOH (0.0429 ml, 0.215 mmol) and 5 drops of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl, and the layers were separated. The organic layer was dried over MgSO.1, filtered and concentrated.
- Step A Ethyl 2-(4-(4-((4-chlorophcnctliyl)carbamoyl)phenoxy)-3-bromophenyl)acctate (Example 46 step C; 40 mg, 0.077 mmol), K 2 CO 3 (32 mg, 0.23 mmol) and 4- (methylsulfonyl)phenylboronic acid (23 mg, 0.12 mmol) were diluted with dioxane (1 mL)/water (300 ⁇ L) followed by the addition of Pd(PPh 3 ) 4 (8.9 mg, 0.0077 mmol). The reaction was purged with nitrogen and stirred at 55°C for 12 hours. The reaction was cooled and concentrated.
- Step B Ethyl 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-4'-
- Step A A mixture of te/7-butyl 2-(3-cyano-4-fluorophenyl)acetate (1.32 g, 5.59 mmol), N-(4-chlorophenethyl)-4-hydroxybenzamide ( 1.85 g, 671 mmol), and potassium carbonate (0.93 g, 6.70 mmol) in DMSO (10 ml) was stirred at 90 0 C for 1 day. The reaction was cooled, diluted with ethyl acetate, and washed with 10% aqueous NazCC ⁇ . The aqueous layer was back extracted with 55 ethyl acetate.
- Step B To tert-Butyl 2-(4-(4-((4-chlorophencthyl)carbamoyl)phenoxy)-3- cyanophenyl)acetate ( 1.09 g.. 2.22 mmol) in 6 ml of 7 N ammonia in methanol at ambient temperature was added Raney-Ni (0.019 g) and the reaction was stirred under a balloon of hydrogen gas at ambient temperature. The reaction was filtered and concentrated to give /er/-butyl 2-(4-(4- ((4-chlorophcnethyl)carbamoyl)phcnoxy)-3-(aminomcthyl)phenyl)acctate (0. 160 g, 15%).
- Step C A mixture of ter/-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3- (aminomethyl)phenyl)acetale (0.015 g, 0.030 mmol), nicotinoyl chloride hydrochloride (0.007 g, 0.039 mmol), and triethylamine (0.013 ml, 0.091 mmol) in dichloromethane (1 ml) was stirred at ambient temperature for 1 hour.
- the reaction was loaded onto a silica gel samplet and the product was eluted using a gradient system of 0.5% methanol/ dichloromethane to 5% methanol/dichloromethanc to provide tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3- (nicotinamidomethyl)phenyl)acetate (0.005 g, 275%).
- Step D To a solution of / «?r/-butyl 2-(4-(4-((4-chlorophencthyI)carbamoyl)phenoxy)-3- (nicotinamidomethyl)phenyl)acctate (0.005 g, 0.008 mmol) in dichloromethane (1.0 ml) was added TFA (1.0 ml) and the reaction was stirred at ambient temperature. After 1 hour the reaction was concentrated to give 2-(4-(4-((4-chlorophenethyl)carbamoyl)phcnoxy)-3-(nicotinamidomethyl) phenyOacctic acid (0.005 g). MS -449.1 [M - CO2H],
- Step A To a stirred solution of tert-butyl 2-(3-(aminonicthyl)-4-(4- (phcnethylcarbamoyl)phenoxy)phenyl)acetatc (0.015 g, 0.030 mmol) in nictlianol (1 ml) was added acetic acid (0.012 ml, 0.212 mmol), sodium cyanoborohydridc (0.010 g, 0.152 mmol) and paraformaldehyde (0.007 g, 0.152 mmol). The reaction was stirred at ambient temperature for 1 hour.
- reaction was loaded directly onto a silica gel samplct and the product elutcd using a gradient of 0.5% mcthanol/dichloromcthanc to 5% methanol/ dichloromcthanc to provide /er/-butyl 2-(4-(4-((4-chloroplienetliyl)carbamoyl)phenoxy)-3-((dimelhylamino)methyl)phcnyl)acetate (0.005 g, 0.010 mmol).
- Step B To tert-bulyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-
- Step A To a stirred solution of tert-buty ⁇ 2-(3-cyano-4-fluorophcnyl)acetatc (1.00 mg, 4.25 mmol) and methyl 4-hydroxybenzoate (776 mg, 5.10 mmol) in DMSO (20 ml) was added K 2 CO 3 (704 mg, 5.10 mmol). The reaction was heated to 90 0 C overnight via an oil bath. The reaction was diluted with ethyl acetate and 10% aqueous sodium carbonate.
- Step B To a stirred solution of the methyl 4-(4-(2- ⁇ ?rt-buloxy-2-oxoethyl)-2- cyanophcnoxy)bcnzoatc (1.086 mg, 2.96 mmol) in 7N ammonia/mcthanol (30 ml) under nitrogen was added Raney Nickel (25.3 mg, 0.296 mmol). The reaction was purged with a hydrogen balloon and stirred under hydrogen overnight. The reaction was filtered through GF paper and the solid catalyst was rinsed with methanol and ethyl acetate.
- Step C To a stirred solution of the methyl 4-(2-(aminomcthyl)-4-(2-re «-butoxy-2- oxoethyl)phenoxy)benzoate (690 mg, 1.86 mmol) in dichloromethane (6 ml) was added pyridine (225 ⁇ L, 2.78 mmol) followed by mclhanesulfonyl chloride (287 ⁇ L, 3.71 mmol). The reaction was stirred at ambient temperature for 4 hours, after which time additional pyridine (1.5 eq) and mcthanesulfonyl chloride (2 eq) were added.
- Step D To a stirred solution of the methyl 4-(4-(2-fm-butoxy-2-oxoethyl)-2- (mcthylsulfonamidomethyl)phenoxy)benzoate (745 mg, 1.65 mmol) in DMF (10 ml) was added McI ( 155 ⁇ L, 2.48 mmol) followed by K2CO3 (343 mg, 2.48 mmol). The reaction was stirred at ambient temperature for 3 hours, then diluted with ethyl acetate and 2M HCI. The aqueous phase was extracted with ethyl acetate, and the combined organic layers were washed with brine and dried 59 over MgS0.».
- Step E To a stirred solution of methyl 4-(4-(2-fc ⁇ f-butoxy-2-oxoethyl)-2-((N- mcthyImethan-2-ylsulfonarnido)methyl)phenoxy)benzoate (370 mg, 0.797 mmol) in dioxane (8 ml) was added a solution of LiOH monohydratc (43.5 nig, 1.04 mmol) in water (2 ml) (0.1 M solution 4: 1 dioxane/watcr). The reaction was stirred for 5 hours, then diluted with dichloromethane and 2N HCl.
- Step F To a stirred solution of 4-(4-(2- ⁇ ?/?-butoxy-2-oxoelhyl)-2-((N-methylmethan-2- ylsulfonamido)methyl)phcnoxy)benzoic acid (50 mg, 0.11 1 mmol) and HATU (46.5 mg, 0.122 mmol) in DMF (1 ml) was added DIEA (23.2 ⁇ L, 0.133 mmol) followed by 2-(4- chlorophenyl)cthanamine (11.2 ⁇ L, 0.11 1 mmol). The reaction was diluted with water and extracted with ethyl acetate. The combined organics were washed with brine and dried over MgSCj.
- Step G To a stirred solution of tert-butyl 2-(4-(4-((4- chlorophcnethyl)carbamoyl)phcnoxy)-3-((N-methylmcthan-2-ylsulfonamido)methyl)phcnyl)acctate (1 1.5mg, 0.019mmol) in dichloromethane (ImI) was added TFA (50OuI). The reaction was stirred at ambient temperature for 4 hours and then concentrated..
- Step A A mixture of /ert-butyl 2-(3-cyano-4-fluorophenyl)acetate (0.122 g), N-(4- chlorophenethyl)-4-hydroxybcnzamide (0.150 g), and potassium carbonate (0.086 g) was dissolved in 2 ml of DMSO and stirred at 90 0 C. After 1 day, the reaction was cooled, loaded onto a silica gel samplct and product eluted with a solvent system gradient of 0.5% methanol/ dichloromethane to 5% methanol/ dichloromethane to give /er/-butyl 2-(3-cyano-4-(4-
- Step B To a solution of tert-butyl 2-(3-cyano-4-(4-(phcncthylcarbamoyl) phenoxy)phenyl)acctate 0. 120 g) in 2 ml of dichloromethane was added 2 ml of TFA and the reaction was stirred at ambient temperature. After 1 hour the reaction was concentrated and dried under vacuum to give 2-(3-cyaiio-4-(4-(phenethylcarbamoyl)phenoxy)phcnyl)acctic acid (0.100 g). MS -355.3 [M - CO2H].
- Step A To a stirred solution of the 4-fluoro-3-(trifluoromethyl)benzaldehyde (177 ⁇ L, 1.30mmol) and N-(4-chlorophenethyl)-4-hydroxybcnzamide (359 mg, 1.30 mmol) in DMSO (3 ml) was added K 2 CO 3 (270 mg, 1.95 tnmol). The reaction was stirred at 95°C for 2 hours and Chen directly purified by silica gel chromatography to give N-(4-chlorophenethyl)-4-(4-formyl-2- (trifluoromethyl)phenoxy)benzamide (0.541 g).
- Step B To a solution of N-(4-chlorophenethyl)-4-(4-formyl-2-
- Step C To (Z)-N-(4-chlorophenethyl)-4-(4-(2-(m ⁇ thylsulfinyl)-2-(melhylthio)vinyl)-2- (trifluoromethyl)phenoxy)bcnzamide (0.220 g, 0.397 mmol) was added HCl (in ethanol) (0.993 ml, 1.99 mmol) and the reaction heated to 7O 0 C for 1 hour. The reaction was concentrated, loaded onto silica gel and the product eluted using a gradient of 5% ethyl acetate/hexanes to 75% ethyl acetate/hexanes. Isolated ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyI)phenoxy)-3-
- Step D To a solution of ethyl 2-(4-(4-((4-chIorophcnethyl)carbamoyl)phenoxy)-3- (trifluoromethyl)phenyl)acetate (0. 165 g, 0.326 mmol) in methanol/THF (1: 1), 5 ml was added LiOH-H 2 O (0.0684 g, 1.63 mmol) and 3 drops of water, and the reaction was stirred for 1 hour The reaction was diluted with ethyl acetate, washed with 2N HCl and brine, dried over magnesium sulfate and concentrated.
- Step A To a stirred solution of diisopropylamine in 2 ml of THF at -78 0 C was added n- butyl lithium (0.61 ml). The reaction was stirred for 30 minutes after which time a solution of tert- butyl 2-(3-cyano-4-fluorophenyl)acetate (0.300 g) in THF (2 ml) was added dropwise over 20 minutes at -78 0 C. The reaction was warmed to 0 0 C and then transferred a flask containing 2 ml THF and MeI (0.080 ml). The reaction was acidified with 2M HCl and extracted with ethyl acetate.
- Step B A flask was charged with ten-butyl 2-(3-cyano-4-fluorophenyl)acetate (0.070 g), N-(4-chlorophenethyl)-4-hydroxybcnzamide (0.105 g), and potassium carbonate (0.047 g) in 1 ml of DMSO and stirred at 95 0 C for one day. The reaction was taken up in dichloromcthanc and washed with water. The organic layer was collected, dried over MgSCU filtered, and concentrated.
- Step C A flask was charged with ⁇ ?r/-butyl 2-(4-(4-((4- chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)propanoate (0.098 g) in 1 ml of dichloromethane and 1 ml of TFA, and the reaction was stirred for 1 hour. The reaction was concentrated and dried under vacuum. Isolated 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3- cyanophenyOpropanoic acid (0.080 g). MS +449.1 [M +1J.
- Step A Methyl 2-(4-hydroxy-3-mctho ⁇ yphenyl)acetate (0.204 g, 1.04 mmol), N-(4- chlorophcncthyl)-4-iodobenzamidc (0.200 g, 0.519 mmol), 2,2,6,6-tetramethyl-3,5-heptanedionc 63
- Step B To a solution of methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3- methoxyphenyl)acetate (0.065 g, 0.143 mmol) in methanol/THF (1: 1, 3 ml) was added NaOH (0.100 ml, 0.500 mmol). After 5 minutes, reaction was quenched with 10 ml of 2N HCl and the product was extracted into ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated.
- the crude material was purified by silica gel chromatography, cluting with a gradient of 0.5% methanol/dichloromcthane (containing 0.5% AcOH) to 7.5% methanol/dichloromethane containing (0.5% AcOH) to provide 2-(4-(4-((4- chlorophenethyI)carbamoyl)phenoxy)-3-mcthoxyphcnyl)acctic acid (0.041 g, 65.1% yield) as a white solid.
- Step A To a stirred solution of 2-fluoro-4-hydroxybenzoic acid (200mg, 1.28mmol) in DMF (3 ml) at ambient temperature were added HATU (536 mg, 1.41 mmol) and DIEA (268 ⁇ L, 1.54 mmol). The reaction was stirred for 30 minutes and then 2-(2,4-dichlorophenyl)ethanamine (193 ⁇ L, 1.28 mmol) was added. The reaction was stirred overnight, then concentrated and diluted with water and dichloromethane. The aqueous layer was extracted with dichloromethane and the combined organic layers were washed with brine and dried over MgSO4. The crude product was purified by silica gel chromatography) to give N-(2,4-dichlorophenelhyl)-2-fluoro-4- hydroxybcnzamide (0.420 g).
- Step B To a stirred solution of N-(2,4-dichlorophenethyl)-2-fluoro-4- hydroxybenzamide (420 mg, 1.28 mmol) and rm-butyl 2-(3-cyano-4-fluorophenyl)acetate (361 mg, 64
- Step C To a stirred solution of /e «-butyl 2-(4-(4-((2,4-dichlorophenethyl)carbamoyl)-3- fluorophenoxy)-3-cyanophenyl)acetatc (15 mg, 0.0276 mmol) in dichloromcthanc was added TFA. The reaction was stirred for 2 hours and then concentrated.
- Step A TFP Resin ( 1.33 mmol/g; 2.872 g, 3.820 mmol) was placed in a vessel and DMA (5 mL) was added to swell the resin. The vessel was placed on a shaker for 15 minutes, and 4-(4-(2-/e/v-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoic acid (1.500 g, 4.245 mmol), DIC (0.7311 ml, 4.669 mmol), and DMAP (0.5704 g, 4.669 mmol) were added to the mixture and the vessel was placed on the shaker.
- Step B TFP resin bound ester (4-(4-(2-t ⁇ rt-butoxy-2-oxoethyl)-2- cyanophenoxy)benzoate) (0.1968 g, 0.09840 mmol) was added to a vial. THF (2 ml) was added and the resin was allowed to swell. 2-(2,6-Dichlorophenyl)ethanamine, (IM in THF; 0.08200 ml, 0.082 mmol) was added to the vial and the vial was place on a shaker. After 16 hours, the mixture was 65 decanted and the resin was rinsed with THF (3 X 2ml). The combined THF solution was concentrated under reduced pressure.
- Step C tert-Butyl 2-(4-(4-((2,6-dichlorophenethyl)carbamoyl)phenoxy)-3- cyanophcnyl)acetate (34 mg, 0.065 mmol) was dissolved in dichloromethane (ImI) and TFA (ImI) was added. After stirring for 45 minutes, the mixture was concentrated under reduced pressure to give 2-(3-cyano-4-(4-(2,6-dichlorophencthyIcarbamoyl)phenoxy)phenyl)acctic acid (0.034 g).
- Step A tert-Butyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phcnoxy)-3-cyanophenyl) acetate (0.400 g) and 4-methylbenzencsulfonyl azide (0.193 g) were dissolved in 5 ml of acetonitrile and treated with DBU (0.152 ml) The reaction was stirred for 4 hours, then concentrated, diluted with ethyl acetate and washed with water.
- Step B A flask was charged with /er/-butyl 2-(4-(4-(4- chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)-2-diazoacetate (0.108 g), 5 ml of ether and HF pyridine (0.30 g). The reaction was stirred at 40 0 C for 30 minutes. The reaction mixture was diluted with ethyl acetate and neutralized with saturated aqueous bicarbonate solution. The organic layer was separated and washed with brine, dried, filtered and concentrated onto silica gel.
- Step C A flask was charged with rm-butyl 2-(4-(4-((4- chlorophencthyl)carbamoyl)phenoxy)-3-cyanophenyl)-2-fluoroacetate (0.026 g), 0.5 ml of dichloromcthanc and 0.2 ml of TFA.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2661164A CA2661164C (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
JP2009525728A JP5582634B2 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
PL07814294T PL2057115T3 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
NZ575507A NZ575507A (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
UAA200902429A UA96459C2 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
ES07814294T ES2396715T3 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
AU2007286829A AU2007286829B2 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
SI200731117T SI2057115T1 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
EP07814294A EP2057115B9 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
RS20120563A RS52627B (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
DK07814294.0T DK2057115T3 (en) | 2006-08-21 | 2007-08-21 | 4-SUBSTITUTED PHENOXYPHENYL ACID ACID DERIVATIVES |
KR1020097005733A KR101397352B1 (en) | 2006-08-21 | 2007-08-21 | 4-Substituted Phenoxyphenylacetic Acid Derivatives |
US12/438,112 US8183289B2 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
MX2009001876A MX2009001876A (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives. |
BRPI0715617-0A2A BRPI0715617A2 (en) | 2006-08-21 | 2007-08-21 | 4-Substituted Phenoxyphenylacetic Acid Derivatives |
IL197135A IL197135A (en) | 2006-08-21 | 2009-02-19 | 4-substituted phenoxyphenylacetic acid derivatives, pharmaceutical compositions comprising them, uses thereof and processes for their preparation |
US13/448,689 US8492437B2 (en) | 2006-08-21 | 2012-04-17 | 4-substituted phenoxyphenylacetic acid derivatives |
HRP20130004TT HRP20130004T8 (en) | 2006-08-21 | 2013-01-03 | 4-substituted phenoxyphenylacetic acid derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83901806P | 2006-08-21 | 2006-08-21 | |
US60/839,018 | 2006-08-21 | ||
US85138506P | 2006-10-13 | 2006-10-13 | |
US60/851,385 | 2006-10-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/438,112 A-371-Of-International US8183289B2 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
US13/448,689 Continuation US8492437B2 (en) | 2006-08-21 | 2012-04-17 | 4-substituted phenoxyphenylacetic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008024746A1 true WO2008024746A1 (en) | 2008-02-28 |
Family
ID=38904570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/076378 WO2008024746A1 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
Country Status (25)
Country | Link |
---|---|
US (2) | US8183289B2 (en) |
EP (1) | EP2057115B9 (en) |
JP (1) | JP5582634B2 (en) |
KR (1) | KR101397352B1 (en) |
CN (1) | CN101553461A (en) |
AU (1) | AU2007286829B2 (en) |
BR (1) | BRPI0715617A2 (en) |
CA (1) | CA2661164C (en) |
CO (1) | CO6160224A2 (en) |
DK (1) | DK2057115T3 (en) |
ES (1) | ES2396715T3 (en) |
HR (1) | HRP20130004T8 (en) |
IL (1) | IL197135A (en) |
MX (1) | MX2009001876A (en) |
MY (1) | MY149934A (en) |
NZ (1) | NZ575507A (en) |
PL (1) | PL2057115T3 (en) |
PT (1) | PT2057115E (en) |
RS (1) | RS52627B (en) |
RU (1) | RU2463292C2 (en) |
SG (1) | SG174069A1 (en) |
SI (1) | SI2057115T1 (en) |
TW (1) | TWI409247B (en) |
UA (1) | UA96459C2 (en) |
WO (1) | WO2008024746A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116145A2 (en) * | 2007-03-22 | 2008-09-25 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
GB2461629A (en) * | 2008-07-03 | 2010-01-13 | Amira Pharmaceuticals Inc | Phenoxy acetic acids as atagonists of prostaglandin D2 receptors |
WO2010075200A1 (en) | 2008-12-22 | 2010-07-01 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
WO2010094956A1 (en) | 2009-02-17 | 2010-08-26 | Pulmagen Therapeutics (Inflammation) Limited. | Triazolopyridine derivatives as p38 map kinase inhibitors |
US20100273850A1 (en) * | 2007-11-05 | 2010-10-28 | Doherty George A | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives |
EP2257536A2 (en) * | 2008-02-14 | 2010-12-08 | Amira Pharmaceuticals, Inc. | Cyclic diaryl ether as antagonists of prostaglandin d2 receptors |
JP2011526290A (en) * | 2008-06-25 | 2011-10-06 | アレイ バイオファーマ、インコーポレイテッド | 6-substituted phenoxycyclomancarboxylic acid derivatives |
US8049015B2 (en) | 2008-09-29 | 2011-11-01 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8067445B2 (en) | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
JP2013516475A (en) * | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | DP2 antagonists and uses thereof |
US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
US8785393B2 (en) | 2009-07-31 | 2014-07-22 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists |
US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
EP4420734A2 (en) | 2015-02-13 | 2024-08-28 | Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101397352B1 (en) * | 2006-08-21 | 2014-05-19 | 어레이 바이오파마 인크. | 4-Substituted Phenoxyphenylacetic Acid Derivatives |
KR20140113667A (en) | 2011-12-16 | 2014-09-24 | 아토픽스 테라퓨릭스 리미티드 | Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
CN104016878B (en) * | 2014-06-24 | 2015-06-10 | 中国药科大学 | Aryl acetic acid derivative as well as preparation method and medical application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058164A2 (en) | 2002-12-20 | 2004-07-15 | Tularik, Inc. | Asthma and allergic inflammation modulators |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026182A1 (en) * | 1998-11-04 | 2000-05-11 | Basf Aktiengesellschaft | 2-phenoxyphenylacetic acid derivatives, method and intermediate products for the production thereof, their use, and agents containing the same for combating fungicidal pests |
JP2001072653A (en) * | 1999-07-01 | 2001-03-21 | Taisho Pharmaceut Co Ltd | Aminobenzoic acid derivative |
GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
JP2002193800A (en) * | 2000-12-22 | 2002-07-10 | Taisho Pharmaceut Co Ltd | Vegf receptor antagonist |
TW200408393A (en) * | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
US7557143B2 (en) * | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
CA2573223C (en) * | 2004-08-06 | 2013-05-21 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compound |
BRPI0712301A2 (en) | 2006-06-09 | 2012-01-17 | Icos Corp | compound, pharmaceutical composition, method of antagonizing a dp-2 receptor, and use of a compound |
KR101397352B1 (en) * | 2006-08-21 | 2014-05-19 | 어레이 바이오파마 인크. | 4-Substituted Phenoxyphenylacetic Acid Derivatives |
-
2007
- 2007-08-21 KR KR1020097005733A patent/KR101397352B1/en not_active IP Right Cessation
- 2007-08-21 TW TW096130898A patent/TWI409247B/en not_active IP Right Cessation
- 2007-08-21 SG SG2011057858A patent/SG174069A1/en unknown
- 2007-08-21 CN CNA200780039235XA patent/CN101553461A/en active Pending
- 2007-08-21 ES ES07814294T patent/ES2396715T3/en active Active
- 2007-08-21 DK DK07814294.0T patent/DK2057115T3/en active
- 2007-08-21 WO PCT/US2007/076378 patent/WO2008024746A1/en active Application Filing
- 2007-08-21 US US12/438,112 patent/US8183289B2/en not_active Expired - Fee Related
- 2007-08-21 PT PT78142940T patent/PT2057115E/en unknown
- 2007-08-21 BR BRPI0715617-0A2A patent/BRPI0715617A2/en not_active IP Right Cessation
- 2007-08-21 JP JP2009525728A patent/JP5582634B2/en not_active Expired - Fee Related
- 2007-08-21 UA UAA200902429A patent/UA96459C2/en unknown
- 2007-08-21 RU RU2009110183/04A patent/RU2463292C2/en not_active IP Right Cessation
- 2007-08-21 EP EP07814294A patent/EP2057115B9/en active Active
- 2007-08-21 SI SI200731117T patent/SI2057115T1/en unknown
- 2007-08-21 RS RS20120563A patent/RS52627B/en unknown
- 2007-08-21 AU AU2007286829A patent/AU2007286829B2/en not_active Ceased
- 2007-08-21 PL PL07814294T patent/PL2057115T3/en unknown
- 2007-08-21 MX MX2009001876A patent/MX2009001876A/en active IP Right Grant
- 2007-08-21 CA CA2661164A patent/CA2661164C/en not_active Expired - Fee Related
- 2007-08-21 MY MYPI20090706A patent/MY149934A/en unknown
- 2007-08-21 NZ NZ575507A patent/NZ575507A/en not_active IP Right Cessation
-
2009
- 2009-02-19 IL IL197135A patent/IL197135A/en active IP Right Grant
- 2009-03-12 CO CO09025722A patent/CO6160224A2/en unknown
-
2012
- 2012-04-17 US US13/448,689 patent/US8492437B2/en not_active Expired - Fee Related
-
2013
- 2013-01-03 HR HRP20130004TT patent/HRP20130004T8/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058164A2 (en) | 2002-12-20 | 2004-07-15 | Tularik, Inc. | Asthma and allergic inflammation modulators |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116145A3 (en) * | 2007-03-22 | 2009-08-27 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
WO2008116145A2 (en) * | 2007-03-22 | 2008-09-25 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
US8362056B2 (en) * | 2007-11-05 | 2013-01-29 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives |
US20100273850A1 (en) * | 2007-11-05 | 2010-10-28 | Doherty George A | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives |
US8338484B2 (en) | 2008-02-01 | 2012-12-25 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
US8168678B2 (en) | 2008-02-01 | 2012-05-01 | Panmira Pharmaceuticals, Inc. | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
US8362044B2 (en) | 2008-02-01 | 2013-01-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
US8067445B2 (en) | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
EP2257536A2 (en) * | 2008-02-14 | 2010-12-08 | Amira Pharmaceuticals, Inc. | Cyclic diaryl ether as antagonists of prostaglandin d2 receptors |
EP2257536A4 (en) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | Cyclic diaryl ether as antagonists of prostaglandin d2 receptors |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
US9096567B2 (en) | 2008-06-25 | 2015-08-04 | Array Biopharma Inc. | 6-substituted phenoxychroman carboxylic acid derivatives |
US8716498B2 (en) | 2008-06-25 | 2014-05-06 | Array Biopharma, Inc. | 6-substituted phenoxychroman carboxylic acid derivatives |
CN103450138A (en) * | 2008-06-25 | 2013-12-18 | 阵列生物制药公司 | Preparation of intermidiates of 6-substituted phenoxychroman carboxylic acid derivatives |
US8569522B2 (en) | 2008-06-25 | 2013-10-29 | Array Biopharma Inc. | 6-substituted phenoxychroman carboxylic acid derivatives |
JP2011526290A (en) * | 2008-06-25 | 2011-10-06 | アレイ バイオファーマ、インコーポレイテッド | 6-substituted phenoxycyclomancarboxylic acid derivatives |
US9556139B2 (en) | 2008-06-25 | 2017-01-31 | Array Biopharma Inc. | 6-substituted phenoxychroman carboxylic acid derivatives |
US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
US8247602B2 (en) | 2008-07-03 | 2012-08-21 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
GB2461629B (en) * | 2008-07-03 | 2010-05-26 | Amira Pharmaceuticals Inc | Antagonists of prostaglandin D2 receptors |
GB2461629A (en) * | 2008-07-03 | 2010-01-13 | Amira Pharmaceuticals Inc | Phenoxy acetic acids as atagonists of prostaglandin D2 receptors |
US8049015B2 (en) | 2008-09-29 | 2011-11-01 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
WO2010075200A1 (en) | 2008-12-22 | 2010-07-01 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
US8785445B2 (en) | 2008-12-22 | 2014-07-22 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
WO2010094956A1 (en) | 2009-02-17 | 2010-08-26 | Pulmagen Therapeutics (Inflammation) Limited. | Triazolopyridine derivatives as p38 map kinase inhibitors |
US8785393B2 (en) | 2009-07-31 | 2014-07-22 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists |
US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
US9688624B2 (en) | 2010-01-06 | 2017-06-27 | Brickell Biotech, Inc. | DP2 antagonist and uses thereof |
JP2013516475A (en) * | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | DP2 antagonists and uses thereof |
WO2012069175A1 (en) | 2010-11-25 | 2012-05-31 | Almirall, S.A. | New pyrazole derivatives having crth2 antagonistic behaviour |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
WO2013010880A1 (en) | 2011-07-18 | 2013-01-24 | Almirall, S.A. | New crth2 antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
WO2013010881A1 (en) | 2011-07-18 | 2013-01-24 | Almirall, S.A. | NEW CRTh2 ANTAGONISTS |
EP4420734A2 (en) | 2015-02-13 | 2024-08-28 | Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2057115B1 (en) | 4-substituted phenoxyphenylacetic acid derivatives | |
JP4330341B2 (en) | Cannabinoid receptor ligand | |
TWI491595B (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
WO1990009997A1 (en) | Novel benzimidazole derivatives | |
WO2001019808A1 (en) | Chemical compounds and compositions and their use as cathepsin s inhibitors | |
CA2518194A1 (en) | 6-substituted nicotinamide derivatives as opioid receptor antagonists | |
US8362056B2 (en) | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives | |
MXPA05006701A (en) | Asthma and allergic inflammation modulators. | |
BR112012026117B1 (en) | PROCESS FOR PREPARATION OF 4-{4-[({[4-CHLORINE-3-(TRIFLUORINE-METHYL)PHENYL]AMINO}CARBONYL)AMINO] -3-FLUORO-PHENOXY}-N-METHYL-PYRIDINE-2-CARBOXAMIDE | |
AU5650299A (en) | Benzene derivatives and medicinal use thereof | |
AU2003226926A1 (en) | Novel methoxybenzamide compounds for use in mch receptor related disorders | |
CA2419722A1 (en) | Benzoic acid derivatives and drugs containing the same as the active ingredient | |
TW200305559A (en) | Process for trans-4-amino-1-cyclohexane carboxylic acid derivatives | |
US7375120B2 (en) | Peptide deformylase inhibitors | |
EP1947097A1 (en) | BENZOÝb¨THIOPHEN DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | |
US20150018411A1 (en) | Compounds as ppar beta/delta inhibitors for treating ppar beta/delta-mediated diseases | |
TW202423902A (en) | Pharmaceutical process and intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780039235.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07814294 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12009500327 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2661164 Country of ref document: CA Ref document number: 197135 Country of ref document: IL Ref document number: MX/A/2009/001876 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009525728 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09025722 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 575507 Country of ref document: NZ Ref document number: 2007286829 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007814294 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1055/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097005733 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: a200902429 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2009110183 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007286829 Country of ref document: AU Date of ref document: 20070821 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12438112 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2012/0563 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: PI0715617 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090220 |